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TRIM28 INTERACTS WITH EZH2 TO REGULATE ITS ACTIVITY 
 
Jing Li, B.M. M.S 
Supervisory Professor: Michelle Barton, Ph.D. 
 
In this dissertation, I discovered that TRIM28 interacts with EZH2 and regulates its 
activity in breast cancer cells.  EZH2, the major H3K27 tri-methyltransferase, is over 
expressed in multiple subtypes of breast cancer; however, whether EZH2 plays an active 
role in breast cancer progression or treatment resistance is unknown. Here, we 
determined EZH2-interacting proteins in MCF7 cells by immunoprecipitation/mass 
spectrometry and detected TRIM28 with a high confidence score. TRIM28 is a 
transcription co-regulator with an N-terminal tri-partite RING finger, B-boxes and a 
coiled-coil domain (RBCC) and a C-terminal PHD/Bromo domain. Domain mapping 
revealed that the RBCC domain of TRIM28 interacts with EZH2, and the pre-SET region 
(Cysteine-rich domain) of EZH2 interacts with TRIM28. Transcriptome profiling and 
intersection of EZH2- and TRIM28-regulated genes indicated co-regulation of 
differentiation and morphogenesis pathways, as well as co-activation of the cytokine-
cytokine receptor interaction pathway (CXCR4, CXCL12, EGFR, KIT). TRIM28 
depletion in MCF7 cells decreased EZH2 recruitment and CXCR4 gene expression, in 
parallel with decreased mammosphere formation. TRIM28 regulation of EZH2 
association with SWI/SNF complex might contribute to this process. Collectively these 
data indicate that EZH2 and TRIM28 regulate breast cancer stem cell maintenance by 
transcriptional regulation of CXCR4 gene expression. 
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In part two, TRIM28 is overexpressed in a human mammary epithelial cells (HMEC) 
model of breast cancer progression; interestingly, TRIM28 is heavily phosphorylated 
(pS824/pS473) in the more aggressive stages of this model. Furthermore, ectopic 
expression of TRIM28 WT and phosphorylation defective forms in HMEC cells indicates 
that TRIM28 promotes cell proliferation in a phosphorylation-dependent manner. 
Genome-wide TRIM28 binding profile analysis revealed transcription factor binding 
motifs, including TCF4 and RBP-J (a Notch effector), at TRIM28 binding sites. The 
promoter of AXIN2, which encompasses a TCF4 binding motif, is a direct transcriptional 
activation target of TRIM28. Collectively, we demonstrated a mechanism of regulation of 
breast cancer cell proliferation by TRIM28 in a phosphorylation dependent manner via a 
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1.1 Breast Cancer 
Breast cancer is heterogeneous, and comprises a heterogeneous collection of 
diseases. It is the uncontrolled proliferation of mammary epithelial or 
myoepithelial cells from mammary gland. The smallest unit of mammary gland is 
terminal duct lobular unit complex. Lobules can generate milk, the thin tubes  
 
 
Diagram 1: Anatomy of the female breast. 
The nipple, areola, lymph nodes, lobes, lobules, ducts, and other parts of the 
breast are shown. http://www.cancer.gov/types/breast 
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named ducts transport the milk from the lobules to the nipple. In addition, normal 
breast tissues also have fat tissue (white fat) and connective tissue, lymph 
nodes, and blood vessels. The anatomy of normal breast is illuminated in the 
diagram 1. 
In general, cancer types are classified by tissue site of their origins. With the 
development of TCGA, molecular abnormalities may be eventually accepted as 
the new paradigm to name cancer types. The most common type of breast 
cancer is ductal carcinoma, which originates from the cells of the ducts. Breast 
lobular cancer is derived from the cells of the lobules; in general, the specific 
types of cancer are named by the anatomical location of tissues it originated from 
in the breast. Invasive breast cancer refers to breast cancer that has spread to 
surrounding tissue, lymph nodes, or organs. 
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Breast Cancer Anatomy 
The following image (Diagram 2) (adapted from American Cancer Society, 
www.cancer.org) is an example of locations of early stage breast cancer. 
 
Diagram 2 Lobular carcinoma in situ 
Adopted from www.cancer.org 
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Cell Types of the Mammary Gland and Luminal Epithelial Differentiation 
The mammary gland is composed of a few types of cells, including epithelial, 
adipose, fibroblasts, immune, lymphatic and vascular cells. They collaborate to 
maintain a functional mammary gland 1. The dysfunction of any one of these cell 
types contributes to breast carcinogenesis.  
1) Mammary luminal epithelial cell 
The markers of epithelial cells are listed in the table 1. Epithelial cell-derived 
mammary tumors constitute the largest percentage of breast cancer types. The 
vast majority of current breast cancer research focuses on the epithelial 
compartment. The epithelium has been shown to contain a stem cell population 
that exhibits considerable regenerative potential to develop within an entire fat 
pad 2. Luminal progenitor cells were assessed regarding responsiveness to 
estrogen, and progesterone and found to be hormone insensitive 3,4. 
 
2) Myoepithelial cells 
Myoepithelial (ME) cells are basally oriented in close contact with the basement 
membrane (BM). ME cells have some of the characteristics of both epithelial and 
smooth muscle (SM) cells. Developmental studies suggested that myoepithelial 
cells originated from luminal epithelial cells.  The myoepithelial cells were 
described previously as the only cell able to repopulate the mammary gland and 
act as mammary stem cells 5. Since then, multi-potent basal stem cells have 
been identified within the myoepithelial compartment 6,7.  
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3) Adipocytes 
Adipocytes account for a large portion of the stromal fat pad. Adipocytes have 
been reported to secrete vascular endothelial growth factor (VEGF) and might 
mediate angiogenesis in the gland 8.  
 
4) Fibroblasts 
Stromal fibroblasts are supporting cells for both epithelial cell survival and 
morphogenesis in the fat pad. They regulate epithelial cell features and the 
epithelial cancer phenotype by synthesizing a number of ECM components, such 
as collagens, fibronectin, and matrix metalloproteinases 9. 
 
5) Vascular and immune cells 
There are many vascular and lymphatic networks throughout the fat pad. It was 
reported that Myoepithelial cell-derived VEGF drives lymph angiogenesis in the 
mammary gland 10.  
 
In addition, GATA3, a luminal epithelial cell marker, is essential for mammary 
gland homeostasis and luminal epithelial differentiation 11,12. Normal epithelial 
cells may exhibit a different ability to interact with basement membrane 13.  
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The identified cell markers of these two different cell types are summarized in the 
following table 1.  
 




	  	   	  	   CK14	  
Luminal	  
Epithelial	  
Cell	  Markers	  	  
CK7	   CK17	  
CK8	   SMA	  
CK18	   MYH11	  
CK19	   deltaNp63	  
MUC1/EMA	   Calponin	  
Alpha6	  Integrin	   Caldesmon	  
BCL2	   β4	  Integrin	  
ER	   Laminin	  
PgR	   Maspin	  
GATA3	   CD10	  
EpCAM	   P-­‐Cadherin	  
Desmin	   Caveolin1	  
	  	   NGFR	  
	  	   	  	   14-­‐3-­‐3σ	  
	  	   	  	   S-­‐100	  
 
In some contexts, basal cells are also referred to as ME cells because of their 
location adjacent to the basement membrane and expression of basal 
cytokeratin. So, basal breast cells have two meanings in the context of normal 
mammary glands14: “( 1 ) it has become a synonym for ME cells and ( 2 ) it 
defines a specific subpopulation of basal CK-expressing cells that may be found 
in either a luminal or basal location” 14.  
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Molecular Subtypes of Breast Cancer 
With the development of molecular biology, scientists and oncologists have 
classified six subtypes of breast cancer subtypes in terms of anatomy and 
molecular biology. Among all of the different types of breast cancers15: Luminal 
A, Luminal B, HER2, Basal, and Claudin low, the ER-positive Luminal breast 
cancers constitute the majority of all breast cancers and are generally treated 
with endocrine therapies16. Triple negative breast cancer (TNBC) generally refers 
to both Basal and Claudin low subtypes, which are the most malignant type of 
breast cancers in terms of clinical prognosis. Triple negative breast cancer was 
defined as estrogen receptor negative (ER-α-), progesterone receptor negative 
(PgR-), and human epidermal growth factor receptor 2 negative (HER2-), and has 
a more aggressive clinical course than other forms of breast cancer since it does 
not respond to anti-ER or anti-HER2 therapy 17.  The triple-negative breast 
cancer subtype is a heterogeneous group that represents 10%-20% of breast 
cancers 18.  
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Adapted from www.cancer.org 
 
 
Clinically, triple negative breast cancer represents the most malignant subtype of 
breast cancer showing the worst prognosis among all of the subtypes 15,19. 
Claudin-low type of breast cancer is relatively less studied compared to basal-like 
type of breast cancer. Basal-like breast cancer was believed to originate from 
myoepithelial cells, but the current clinical concept is that basal like breast cancer 
originated from both epithelial and myoepithelial cells. The gene-expression 
profile of basal-like tumors is reportedly similar to the transcriptome profile of 
tumors of BRCA1-germline mutation patients and also suggested its genetic 
signature is a less differentiated “stem/progenitor” cell phenotype or a stem cell 
origin for basal-like tumors 17.  
 
Table 2 Six Subtypes of Breast Cancer 
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The Incidence (Prevalence) of Breast Cancer 
According to American Cancer Society, Breast cancer is the most common 
cancer among American women. About 12% of women in the US will develop 
invasive breast cancer during their lifetime. The 2015 estimation is that about 
231,840 new cases of invasive breast cancer will be diagnosed, and about 
60,290 new cases of carcinoma in situ (CIS) will be diagnosed. In addition, the 
estimated breast cancer death is about 40,290 in the USA in 2015. Among all of 
the reasons for death, distant metastasis is responsible for 90% of deaths among 
breast cancer patients.  
 
Diagram 3 Estimated New Cancer Cases in the US in 2015 
Adapted from www.cancer.org 
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Clinical Stages of Breast Cancer 
The AJCC (American Joint Committee on Cancer) TNM system is the most 
common system used to describe the stages of breast cancer. The TNM 
pathological staging system classifies cancers based on their T, N, and M stages 
(www.cancer.org): 
• The letter T followed by a number from 0 to 4 describes the tumor's size 
and spread to the skin or to the chest wall under the breast. Higher T 
numbers mean a larger tumor and/or wider spread to tissues near the 
breast.  
• The letter N followed by a number from 0 to 3 indicates whether the 
cancer has spread to lymph nodes near the breast and, if so, how many 
lymph nodes are affected. 
• The letter M followed by a 0 or 1 indicates whether the cancer has spread 
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Mortality (Survival Rate) of Breast Cancer Patients 
The five-year overall survival rate of breast cancer is over 90%. The survival 
rates of breast cancer patients are correlated with clinical stages, the table of 
survival rate below was adopted from the National Cancer Institute’s SEER 
database (http://seer.cancer.gov/data/).  
 










Diagram 4 Estimated Cancer Death in the US in 2015 Adopted from www.cancer.org 
 
Table 3 Survival Rates of Breast Cancer 
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Among women, lung (26%), breast (15%), and colon & rectum (9%) cancers are 
the leading causes of cancer death. Thus, the development of better breast 
cancer therapy is greatly needed, and this will be facilitated by a deeper 
understanding of molecular mechanisms. 
 
1.2 Breast Cancer Stem Cell 
The cancer stem cell theory states that tumor proliferation originates from a rare 
subpopulation of tumor cells 20.  This subpopulation of cancer stem/progenitor 
cell is believed to be responsible for cancer initiation, cancer progression, and 
cancer chemotherapy resistance.  Cancer stem/progenitor cells are resistant to 
chemotherapy treatment 21,22 and also contribute to one hallmark of cancer: 
heterogeneity 23. Cancer stem cells are characterized by the ability to undergo 
both self-renewal and differentiation, the differentiated cancer cells constitute the 
bulk of the tumor without tumorigenic capacity as they have a limited capacity to 
self-renewal and low proliferation potential 24,25.  
 
The concept of cancer stem cells was first proposed almost 150 years ago 
20,25,26. However, it was not supported by experimental evidence until 1997 20,25,26. 
The first experimental evidence showed that human leukemia is driven by a small 
number of leukemic stem cells that is able to reconstitute the leukemia in 
NOD/scid mice 27. Cancer stem cells in solid tumors were experimentally 
supported in 2003 using breast cancer cells 23. The breast cancer stem cell was 
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defined as a CD44+CD24- population of breast cancer cells 23.  Other than CD44, 
CD24 breast cancer stem cell marker mentioned above,  
CD133 28, CXCR4 29, EpCAM 30, and ALDH1 25,31 were also reported to express 
on breast cancer stem cells and was suggested to serve as breast cancer stem 
cell markers.  Additionally, Hoechst negative side population (SP) cells, defined 
by flow cytometry of hematopoietic malignancy cells, were also reported to 
exhibit self-renewal properties 32. Spheroid cultures of mammosphere were 
developed as a simple method to measure cancer stem cell populations 31,33. 
Breast cancer stem cells have the capacity to be serial transplanted and 
expanded in immunodeficient mice. The following diagram 2 briefly explains the 
cancer stem cell concept and characteristics. 
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Figure 1- 1 Schematic representation of Cancer stem cell differentiation. 
Reprinted with permission from Adopted from Nature Clinical Practice Neurology 
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1.3 The Link between Epigenetics, Cancer, and Breast Cancer 
Epigenetics refer to heritable changes without alteration of genomic DNA 
sequence, including histone modifications, ATP-dependent chromatin 
remodeling, non-coding RNA-mediated gene silencing, and DNA methylation34; 
histone modifications include acetylation, methylation, ubiquitination and others. 
Epigenetics is implicated in many biological processes such as genomic 
imprinting, X chromosome-inactivation, reprogramming in embryogenesis, and 
chromosomal structure. There has been an explosion of knowledge in our 
understanding of molecular mechanisms of epigenetics of late, especially with 
regards to histone methylation marking gene activation/repression. H3K4me2/3 
is correlated with activated gene expression; whereas, H3K27me2/3 marks 
repressed gene expression. These histone modification markers are catalyzed by 
highly specific enzymes, for example, EZH2 writes H3K27me2/3 by adding 
methyl groups on histone H3 lysine 27 and LSD1 (KDM1A) erases H3K4me/2/3 
by removing methyl group from histone H3K4me/2/3.  
There are many misregulated epigenetics mechanisms uncovered in cancers, 
such as the following: BRD4, a bromodomain protein that “reads” and interacts 
with acetylated lysines 35, emerged as a therapeutic target in acute myeloid 
leukemia, due to its aberrant over expression. JQ1 was developed as a BRD4 
inhibitor and has shown potential in different diseases36. KDM2A promotes lung 
tumorigenesis by increasing ERK1/2 signaling activity 37. Somatic mutations of 
epigenetic molecule were discovered in cancers, such as the histone H3K27M 
mutation in paediatric glioblastoma, ATRX (α-thalassaemia/mental retardation 
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syndrome X-linked) and DAXX (death-domain associated protein) in pediatric 
glioblastoma 38, methylcytosine hydroxylase TET2 in myelodysplasia and myeloid 
malignancies 39, DNA methyltransferase DNMT3A 40, and histone H2K27 
methyltransferase EZH2 in various cancers 41. 
lysine methyltransferases 
SET domain catalyzes protein methylation, both histone and non-histone 
proteins. Histone H3K27 is methylated by EZH2/EZH1, and demethylated by 
UTX. SMYD3, SETD7, and MLLs catalyze H3K4 methylation42, SUV39 family 
add methyl group on H3K9; SET2 family methylates H3K9, H3K27, and H4K20. 
A new class of methyltransferases, PRDM family, catalyzes H3K9 methylation 43. 
 
1.4 Polycomb Repressive Complexes 
Polycomb repressive complexes are transcriptional repressors governing 
development, pluripotency, senescence, and cancer 44. There are two 
multiprotein PcGs complexes, PRC2 and PRC1. 
1) PRC2 Complex - (Polycomb Repressive Complex2) 
The canonical PRC2 complex is comprised of EZH2, EED, SUZ12, and RBBP4, 
its main function is transcriptional suppression by writing di and tri methyl group 
onto histone 3 lysine 27 45. Among the four core subunits, EZH2 is the catalytic 
unit, the major H3K27 tri-methyltransferase 46-49, writes H3K27me2/3 by adding 
methyl group on histone H3 lysine 27. PRC2 plays a critical role in various 
biological processes, ranging from differentiation, maintaining cell identity and 
proliferation, to stem-cell plasticity 50. EZH2 must associate with RBBP4, SUZ12, 
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and EED to exhibit an intact histone 3 lysine 27 methyltransferase activity51,52. In 
other word, all of the four core members of PRC2 are required for EZH2 to 
effectively methylate H3K27 53-55. Once EZH2 no longer associates with its PRC2 
partners, EZH2 can function as a transcriptional co-activator 56. In blood 
development, EZH1 is an alternative enzyme to catalyze histone 3 lysine 27 49,57. 
However, the core subunits of PRC2 complex are not sequence-specific DNA-
binding proteins, and PRC2 must be recruited by other factors: JARID2 58,59, 
AEBP2 60, long non-coding RNAs 50, and more recently, ATRX 61, are identified 
to recruit/direct the PRC2 complex to various target loci to silence gene 
expression. PRC2 preferentially occupies CpG-rich regions, as has been 
reported for PRC2 enrichment of binding at CpG sites in ES cells 62. However, it 
is not known whether there is a similar recruitment mechanism in breast cancer 
development.  
2) PRC1 Complex - (Polycomb Repressive Complex1) 
Polycomb repressive complex 1 composition is quite complicated 44,63. The 
composition of different PRC1 complexes is programmed by the presence or 
absence of CBX proteins (canonical versus non-canonical) and some other 
proteins, such as PCGF (polycomb group factor), HPH (human polyhomeotic 
homolog), and the E3-ligase protein (RING) that catalyzes H2AK119ub44. The 
canonical function of PRC1 is to repress gene expression dependent on its 
ubiquitination enzymatic activity 64, but PRC1 was shown to also activate 
transcription in the CNS 45.  
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Figure 1- 2 Schematic representation of Polycomb complex PRC1/2. 
Reprinted with permission from Nature. 2011 Jan 20; 469(7330): p.343-9 
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1.5 EZH2 - Enhancer of Zeste Homolog 2 
EZH2 is over-expressed and act as an oncogene in various cancers such as 
melanoma, lymphoma, and poorly differentiated synovial sarcoma 65, and 
prostate and breast cancer.  
 
EZH2 in Breast Cancer 
EZH2 is a marker of aggressive breast cancer. Overexpression of EZH2 also 
promotes neoplastic transformation of normal prostatic cells and hyperplasia in 
breast epithelium. The transcriptional repressive role of EZH2 is associated with 
the entire intact PRC2 complex, which is described in the above. However, 
emerging evidences in cancer research indicate that EZH2 play an oncogenic 
role in various types of cancers, which is correlated with EZH2’s transcriptional 
co-activator functions. In breast cancer, EZH2 was reported as a transcriptional 
co-activator by wiring estrogen pathway with WNT proliferation pathway in breast 
cancer66, this raise a deeper question, whether EZH2 play a key role in drug 
resistant breast cancer. As an oncogene, EZH2 inhibitor as a promising anti-
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Figure 1- 3 Chromatin properties at PRC2 target genes in ES cells and 
differentiated cells. Schematic representation of chromatin at PcG target 
genes as a function of ES cell differentiation.  Reprinted with permission from 
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Somatic Mutation of EZH2  
EZH2 somatic mutation at Tyr641 occurs in 21.7% of GCB DLBCLs (GCB 
subtype of diffuse large B-cell lymphoma) and 7.2% of FLs (follicular lymphoma), 
but no mutations were found in ABC DLBCLs (activated B-cell) 67. A gain of 
function for H3K27me3 mutations was first proposed and is now verified 67,68. A 
longitudinal analysis of mutation status, during follicular lymphoma (FL) 
progression from FL to transformed FL, validated frequent mutation status of 
EZH2 in FL patients and also revealed that EZH2 hotspot mutation (3 recurrent 
mutation hot spots (Y646, A682, and A692)) is an early event in FL 69.  
 
Targeting Mutated EZH2 
Therapeutically, the GSK (GSK-126) 70 and Epizyme (EZH2 inhibitors: EPZ-
6438) 71 are two pioneer inhibitors focused on targeting the catalytic SET domain 
of mutant EZH2 in patients with non-Hodgkin lymphomas, including germinal 
center diffuse large B-cell lymphoma (GCB-DLBCL), primary mediastina B-cell 
lymphoma (PMBCL) and follicular lymphoma. This year, EPZ011989, a potent, 
selective, orally bioavailable inhibitor of EZH2 was developed with better 
characteristics of a therapeutic 72. Novartis is developing its own EZH2 SET 
domain targeting inhibitor named EI170, as is Pfizer 73.  Clearly there is 
considerable interest in EZH2 as a therapeutic target. 
 
Targeting EZH2 in a mutated SWI/SNF Background 
In both drosophila and mammals, the PRC2 complex was reported to genetically 
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antagonize SWI/SNF complex 74. But the functional interplay of these two 
complexes might be far more complicated in cancer biology. Immunologists 
showed that PRC2 may inhibit immune surveillance, and EZH2 could be targeted 
to reactivate immune surveillance in SWI/SNF deficient cancers 75.	  
Therapeutically, EPZ-7438 exhibits great efficacy in SMARCB1-deleted pediatric 
malignant rhabdoid tumors (MRT) cells 71. EZH2 inhibition may also sensitize 
BRG1 and EGFR mutant small lung tumors to TopoII inhibitors 76. In ovarian 
cancer, ARID1A mutated in about 50%, and EZH2 inhibition in this genetic 
context exhibited synthetic lethal capacities 77.   
 
EZH2 in Cancer Stem Cell 
The first publication of EZH2 functioning in cancer stem cells was that EZH2 
maintains glioblastoma stem cells 78. EZH2 was reported to function in promoting 
breast cancer initiating cell by activating RAF1-ß-Catenin signaling 79. Another 
lab reported that EZH2 expanded a breast cancer stem cell population by 
activating NOTCH signaling in an H3K27me3 independent manner80. In addition, 
EZH2 drives a cancer malignant phenotype in a polycomb-independent manner, 
but in a SET catalytic domain dependent way in castration-resistant prostate 
cancer56. The authors proposed potential non-histone substrates of EZH2 are 
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EZH2 Catalyzes Non-Histone Substrates 
There are at least three non-histone substrates of EZH2 identified to play critical 
roles in disease biology or cancer biology recently, for example: STAT3 in 
glioblastoma 81, RORα 82 and GATA4 in heart development 83.  
 
The Post-Transcriptional Modification of EZH2 
The high level of EZH2 protein in cancer may be due to decreased negative 
regulators, such as microRNAs. MicroRNA101 is the first identified post-
transcriptional regulator of EZH2 and was identified in prostate cancer 84. Later, 
the low level expression of microRNA101 is also observed in other cancers 85,86. 
Further, more microRNAs are identified to directly regulate EZH2. MiR-26a 87, 
miR214 88, and microRNA124 89 were experimentally shown to target EZH2. 
 
The Post-Translational Modification of EZH2 
EZH2 is phosphorylated at threonine residues 345 and 487 by CDK1 (cyclin-
dependent kinase-1) to exhibit enhanced affinity with RNAs, such as HOTAIR 
and 5’ end of Xist 90,91; another group reported that CDK1 and CDK2 
phosphorylate EZH2 at threonine 350 in an evolutionarily conserved motif that is 
critical for proper EZH2 recruitment and maintaining H3K27me3 mark 90. 
Phosphorylation may also destabilize EZH2 by affecting proteasome dependent 
degradation 92. P300/CBP-associated factor (PCAF) was demonstrated to 
acetylate EZH2 at K348 to regulate its stability and function in lung carcinoma 
progression 93. 
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1.6 Bivalent Genes 
--The coexistence of H3K4m3 and H3K27me3 on nucleosomes 
Almost 4000 promoters in human embryonic stem cells (2984 in mouse ESC) 
contain bivalent chromatin domains that combine the activating H3K4me3 mark 
and the repressive H3K27me3 mark within a single nucleosome 94,95. H3K27me3 
is generally associated with decreased gene expression; however, the bivalency 
status of H3K27me3 does not correlate with gene expression in embryonic stem 
cells 94. These special chromatin structure domains poise expression of lineage-
specific developmental genes in ESC to support timely activation in the presence 
of differentiation signals.  
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Figure 1- 4.  Reprinted with permission from A double take on bivalent 











Copyright (c) 2015 Jing Li, All rights reserved
	   27	  
Figure 1- 5.  Reprinted with permission from Asymmetrically modified 
nucleosomes expand the histone code Nature Structural & Molecular Biology 





The bivalent domains also exist in cancer cells and have been mapped at sites 
that partially overlap with bivalent genes in ES cells 98,99. The bivalent genes in 
cancer tend to be predisposed for late DNA methylation 100. Collectively, these 
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data support a stem cell origin for cancer with a possible link between bivalent 
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1.7 TRIM28 - Tripartite Motif Containing Protein 28,  
Transcription Intermediary Factor 1β, KAP1 
 
Transcriptional Repressor Functions of TRIM28 
TRIM28 (KAP1, KAP-1, TIF1β) is a heterochromatin protein that belongs to the 
tripartite motif superfamily. The tripartite motif is composed of a RING finger 
followed by two B-boxes and a coiled-coil domain, also called RBCC motif; 
TRIM28’s C-terminal is composed of a bi-partite motif encompassing a PHD 
finger and a Bromo domain. TRIM28 was known as a universal transcription 
corepressor protein by interacting with Kruppel associated box (KRAB)-domain 
containing zinc finger proteins 102,103. TRIM28 binds and co-localizes with HP1 
(heterochromatin protein 1) through a well-defined peptide motif, PxVxL. HP1 
reads H3K9me3 (a repressive histone marker) with its chromo domain to play a 
pivotal role in heterochromatin mediated gene silencing 104. TRIM28 depletion 
leads to a lower level of global H3K9me3 105,106. TRIM28 binds and recruits 
SETDB1 complex to H3K9me3 genomic sites mediating heterochromatin 
silencing 107. TRIM28 has sumo E3 ligase activity and exhibits a self - 
sumoylation phenomena at K779, K804, and K554 via its PHD domain 108. 
SETDB1 and CHD3 were shown to bind SUMO-modified KAP1 via their 
functional SIM motifs108,109. TRIM28 was purified by interacting with TRIM24 
(TIF1 α) and TRIM33 (TIF1γ), forming a macromolecular complex to regulate 
transcription. Somatic, hepatocyte-specific deletion of TRIM28, TRIM24, or 
TRIM33 causes mouse hepatocellular carcinoma 110. The histone-binding 
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signature of TRIM28 remains elusive so far, though TRIM24 binds and reads un-
methylated H3K4 and H3K23ac 111, TRIM33 reads K9me3 and K18ac 112.  
 
 
Figure 1- 6  Schematics of the human TRIM28 protein (also called TIF1β and 
KAP1) and other related proteins, including TIF1α/TRIM24, TIF1γ/TRIM33, 
and TIF1δ/TRIM66. Reprinted with permission from Journal of Biological 
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TRIM28 and Stem Cell Pluripotency, Self-Renewal 
Large genome wide RNAi screening revealed that TRIM28 is required for 
maintenance of mouse stem cell pluripotency and self-renewal 114. This pro-
pluripotency function of TRIM28 acts in a phosphorylation (C-terminal serine 824) 
dependent manner 115. Phosphorylated form of S824 TRIM28 is the major form of 
TRIM28 in embryonic stem cell. pSer824 TRIM28 specifically interacts with 
OCT3/4, and subunits of the SWI/SNF2, such as Smarcad1, Brg-1, and BAF155 
to induce ES cell-specific genes, such as SOX2, NANOG, OCT3/4,  and maintain 
pluripotent status of mouse ES cells. In addition, TRIM28 dependent pluripotency 
in mouse stem cell may involve TRIM28-mediated repression of retrotransposon-
based enhancers 116, as well as TRIM28 cooperative interactions with PRC1 to 
activate pluoripotency-associated genes in embryonic stem cell 117.  
 
TRIM28 with Endogenous Retroviral Elements 
Endogenous retroelements account for more than 40% of the mammalian 
genome; and at least 25% of endogenous retroelements is comprised of 
endogenous retroviral elements (ERVs). TRIM28 is known to silence the 
transposable elements of endogenous retroviral elements in embryonic stem 
cells and during early embryonic development 118,119. This process might involve 
recruitment of DAXX to ERVs along with ESET 119. A TRIM28 complex also was 
linked to epigenetic silencing of the retrovirus murine leukaemia virus (MLV) in 
embryonic cells 120. 
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Transcriptional Activation and non-Transcription Roles of TRIM28 
Despite the many studies of TRIM28 as a co-repressor of transcription, recent 
studies indicate that TRIM28 may also activate gene expression in specific 
contexts 113,121. Using ChIP-sequencing technology, genome-wide binding 
profiles of TRIM28 indicates that TRIM28 plays a role distinct from transcriptional 
repression at the majority of its strongest binding sites 121. 
 
TRIM28 and DNA DSB Repair 
TRIM28 is phosphorylated at serine 824 at DNA double strands break sites by 
ATM/ATR to recruit DNA repair machinery 122. Phosphorylation of S824 TRIM28 
was reported to colocalize with γH2AX foci at damage sites and lead to 
constitutive chromatin relaxation in response of DNA double-strand breaks 122. 
TRIM28 is also phosphorylated at serine 473 and is diffusely localized in the 
nucleus by CHK1/2 to positively regulate DNA damage pathway 123.  
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Figure 1- 7 Model for TRIM28 involvement in DNA repair.. Reprinted with 
permission from Journal of Biological Chemistry. 2011 Jul 29; 286(30): p. 26267–
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TRIM28 and Virus Infection 
TRIM28 was also reported to inhibit HIV integration by interacting with acetylated 
integrase and inducing its deacetylation 124.  Human cytomegalovirus (HCMV) 125 
can establish life-long time latency infection in hematopoietic stem cell with the 
help of TRIM28 as a transcriptional repressor.  As soon as TRIM28 is 
phosphorylated by pharmacological approach, HCMV latency is broken; HCMV is 
released from hematopoietic stem cell. There is a unique SUMO-interacting motif 
(LANASIM) in Kaposi's sarcoma-associated herpesvirus (KSHV) encoded LANA 
protein that binds with sumoylated TRIM28 to mediate viral episome 
maintenance and lytic gene silencing 126.  
 
Phosphorylation Switch of TRIM28  
Un-phosphorylated form of TRIM28 and phosphorylated form of TRIM28 appear 
to have different affinities for TRIM28 binding proteins. There is evidence for a 
phosphorylation switch of TRIM28 to regulate MyoD function. In myoblasts, 
TRIM28 serves as a scaffold to recruit not only coactivators such as p300 but 
also corepressors such as G9a and HDAC1 (histone deacetylase 1) to silence 
gene expression. Upon differentiation, phosphorylation of TRIM28 releases the 
corepressors from the scaffold, activating transcription to drive myogenesis 127.  
 
TRIM28 and DNA Methylation in Imprinting Loci 
Daniel Messerschmidt and Barbara Knowles reported that maternal Trim28 
knockout results in a highly pleiotropic, 100% embryonic lethality. The underlying 
Copyright (c) 2015 Jing Li, All rights reserved
	   35	  
mechanism in details is epigenetic misregulation of genomic imprinting loci in 
TRIM28 null mice, mainly through the H19/Igf2 cluster. TRIM28 binding to 
differentially methylated regions (DMRs) is DNA methylation dependent128. 
ZFP57 is required in TRIM28 mediated DNA methylation at imprinted loci 129-131. 
A methylated hexanucleotide TGCCGC was discovered as the motif to be 
recognized by ZFP57/TRIM28 in imprinting control regions (ICRs); H3K9me3 is 
also involved in this mechanism working together with DNA methylation.  
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1.8 Aims of the Work 
The oncogenic role of EZH2 in breast cancer lacks detailed mechanisms, which 
dampen the development of EZH2 based therapy. In the studies described 
herein, we document the physical and functional interactions of TRIM28 with 
EZH2 and demonstrate that TRIM28 collaborate with EZH2 to regulate breast 
cancer stem cell maintenance. We found a specific interaction of EZH2 with 
TRIM28 and discovered that TRIM28 collaborates with EZH2 to regulate breast 
cancer stem cell maintenance by activating CXCR4 signaling pathway. 
Mechanistically, TRIM28 reprograms H3K27me3 distribution.  Depletion of 
TRIM28 does not affect EZH2 expression levels in both MCF7 and HMEC cells, 
but decreases EZH2 recruitment at target genes, which is correlated with 
decreased gene expression. We also documented that TRIM28 is overexpressed 
in HMEC model of breast cancer progression; interestingly, TRIM28 is heavily 
phosphorylated (pS824) in aggressive breast cancer cells. Additionally, 
exogenous TRIM28 expression in HMEC cells increases cell proliferation in a 
phosphorylation dependent manner.  Further analysis revealed that 
phosphorylated TRIM28 (pS824/pS473) does not bind to EZH2, suggesting a 
phosphorylation dependent precise signaling mechanism governing these 
interactions.  
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2.1 Cell Culture, Vectors, and protein purification.  The breast cancer cell line 
MCF7 and the immortalized human mammary epithelial cell line MCF10A were 
obtained from the American Type Culture Collection (ATCC) and grown in 
suggested media conditions. HMEC (Human Mammary Epithelial Cell) cells were 
gifts (http://hmec.lbl.gov/mindex.html) from Dr. Martha Stampfer who was a 
professor at Lawrence Berkeley National Laboratory. HA-TRIM28 CS2 backbone 
plasmid was a gift from Dr. Patrick Ryan Potts 132. To clone TRIM28 into a flag 
tagged vector, full length TRIM28 was amplified with added restriction enzyme 
sites in the amplification primers. The amplicon was digested with the restriction 
enzyme for 2 hours, and subject to gel purification. The purified PCR product was 
incubated with vector for 1 hour at room temperature along with T4 ligase. And 2 
ul of the reaction system was transformed into DH5a E Coli.. Colonies was 
picked up for sequencing for verification at MD Anderson Cancer Center DNA 
analysis core. MBP-EZH2 construct was generated in the lab, and purified from 
E.Coli. With MBP beads (NEB); GST-TRIM28 full length and RBCC fragment 
was also purified from E.coli. 
 
2.2 Mutagenesis and Mutants 
To generate various deletion and point mutants of HA-TRIM28 and Myc-EZH2, 
point mutagenesis protocol (Stratagene/Agilent) was used. Site-specific point 
mutations and serial domain deletions are introduced to HA-TRIM28 and Myc-
EZH2 plasmid using QuickChange® Site-Directed Mutagenesis Kit 
(Stratagene/Agilent), according to manufacturer’s suggestions with slightly 
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medication, KOD DNA polymerase (Millipore) was used to generate mutated 
plasmids instead of PfuUltra HF DNA polymerase. Dpn I was used to digest the 
template DNA for 2 hours. 2ul of amplicons were subject to transformation. And 2 
ul of transformation is then plated on LB agar plates and incubated at 37°C 12-16 
hours or overnight. DNA isolated from E. coli culture is purified using DNA 
Miniprep Kit (Qiagen). Specific mutations were confirmed with Sanger 
sequencing by M.D. Anderson DNA Analysis Core Facility. 
 
2.3. Transient DNA Plasmids Transfection 
To map the interaction domains of EZH2 and TRIM28, MCF7 or HEK-293T cells 
cultured in 10cm plates were co-transfected with HA-TRIM28 and Myc-
EZH2/Flag-EZH2 using Effectene (Qiagen), according to manufacturer’s 
instructions. Briefly, 2 µg of each DNA plasmids was re-suspended in 200µL EC 
Buffer, together with 16µL Enhancer and vortexed for 5 seconds. After 5 minutes 
of incubation at room temperature, 20µL of Effectene was added to the mixture, 
and vortexed for 10 seconds. After 10 minutes incubation at room temperature, 
medium is added to reach 800 µL volume in total and gently transferred onto the 
cells. Protein is harvested 30-48 hours after transfection.  
 
2.4. Transient knockdown by siRNAs 
MCF7 cells cultured at 6-well plates are transfected with siControl, 
siTRIM28 (ON-TARGETplus SMARTpool, Dharmacon) using Lipofectamine® 
RNAiMAX transfection reagent (Invitrogen), according to manufacturer’s 
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instructions 111. Briefly, for each transfection, 100 pmol of siRNA and 5 µL 
Lipofectamine RNAiMAX was first separately re-suspended into 250 µL 
completed medium and incubated at room temperature for 5 min. Then, siRNAs 
and Lipofectamine RNAiMAX are mixed together and further incubated at RT for 
10 minutes. Cells covered with 250 µL medium are then transfected with the 
siRNA-Lipofectamine RNAiMAX mixture. Medium is changed after 4 to 6 hours 
and cells are continually cultured for a total of 48-72 hours before harvest.  
 
2.5 Lenti-Viral Infections, establishment of stable knockdown cell lines. 
EZH2 knockdown was achieved by using stable pGIPZ short-hairpin interfering 
RNA in lentivirus (V2LHS_17507, open biosystems). A lentiviral scramble 
plasmid was used as control for transfection and virus packaging. The virus 
packaging protocol was reported previously 133. Briefly, equal amount of shEZH2 
plasmid was co-transfected with pPAX2, and pMAX into HEK293T cells to 
generate virus. After 48 hours, the supernatant was filtered and transferred into 
targeted cell lines for infection for two to three days. Then, 2ug/ml puromycin 
(Sigma) was added for selection for MCF7 cells, 1ug/ml for HMEC cells; 
puromycin selection lasts one to two weeks.  And western blotting was used to 
test whether the cells were successfully knocked down. Once the knockdown 
efficiency is verified, maintenance concentration of 0.2 ug/ml of puromycin was 
used. 
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2.6 Western Blots. MCF7 cells were lysed in NTEP buffer (25mM Tris-HCl pH 
7.5, 150mM NaCl, 5mM EDTA, 0.5% NP-40) for 30 min at cold room for western 
blot. Generally, 20ug protein lysate was loaded into various percentages of SDS-
PAGE gels. PVDF membrane was used for transferring, 5% milk or BSA was 
used for blocking, 3% milk or BSA was used to dilute primary (dilute at 1:1000 to 
1:5000) and secondary antibodies (dilute at 1:5000 to 1:10000) and incubate with 
membrane. Primary antibody was incubated with membrane for 2 hours at room 
temperature or overnight at cold room, and membrane was washed extensively 
for 3 times, 10 minutes each time. Secondary antibody was incubated with 
membrane for 45-60 minutes. 
List of antibodies used in the project: 
EZH2,             Active Motif, #39875, #39933, Cell Signaling, Rabbit mAb#5246  
TRIM28,          Ab10483, Ab22533, Santa Cruz, SC-33186 (H300) 
SUZ12,             Abcam, ab12073;  
EED,                 GeneTex, GTX628007;  
RBBP4,             GeneTex, GTX62136;  
TRIM33,             Abnova, #51992-M01;  
HA,                     Roche, 12CA5;  
Myc,                    Santa Cruz, SC-40 (9E10) 
pS8244TRIM28,  Bethyl Laboratory, A300-767A 
pS473TRIM28,    Biolegend, #644602 
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2.7 Immunoprecipitation, Mass Spec. MCF7 and HMEC cells were lysed in 
NTEP buffer (25mM Tris-HCl pH 7.5, 150mM NaCl, 5mM EDTA, 0.5% NP-40) for 
30 minutes at cold room. The cell lysate were cleaned by high-speed 
centrifugation, 14,000rpm for 10 minutes. Protein concentration was measured 
with BCA assay. 500ug cell lysate was used to incubate with either EZH2, 
TRIM28, pS473TRIM, pS824TRIM28 antibodies overnight in the cold room. Then 
protein A Sepharose beads (GE Health) were added for additional 2 hours 
incubation. After extensive washing, 35ul SDS loading dye was added into the 
beads, the beads was boiled for 5-10 minutes to elute the protein complex. Elute 
was then subject to western blot in various percentage of SDS-PAGE gels. Gel 
was cut and sent out for mass spec at UTMB proteomics core.  
 
2.8 Mammosphere Assay. Single-cell association for mammosphere formation 
assays was performed in six well plates following established protocols with 
MCF7 cells and derived mutant cell lines at a density of 1X104 cells/mL. 
Mammospheres were cultured in MammoCult Human Basal Medium with added 
proliferation Supplement (Stem Cell Technologies, BC, Canada) on Costar Ultra 
Low Attachment tissue culture plates. After 7 days, mammosphere sizes and 
numbers were determined using an inverted microscope at MD Anderson Cancer 
Center. Mammosphere sizes were measured as the widest diameter with the 
scale bar of the microscope. The mammosphere was counted only if its diameter 
is greater than 70µm. All experiments were done in triplicate.  
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2.9 RNA extraction, and real-time RT-PCR  
RNA extraction, cDNA synthesis, Realtime RT-PCR is routinely used in our lab 
111,133. Briefly, total RNA was extracted with Trizol (Invitrogen) according to 
manufacturer’s suggestions. Then,1ug of total RNA was used for reverse 
transcription into cDNA, Each real time PT-PCR reaction mix, containing 2µL of 
dilutes cNDA (1:10 dilution), 5µL SYBR Green Reaction Mix (Applied 
Biosystems), 0.25µL forward primer (20µM), 0.25µL reverse primer (20µM), and 
2.5µL sterile water, is set up in a 96-well plate and performed in triplicate using 
Applied Biosystems RT-PCR system at MD Anderson Cancer Center with SYBR 
Green Master Mix.  Gene expression levels were calculated following 
normalization to Beta-Actin levels using the comparative Ct (cycle threshold) 
method. The primer sequences used for RT-PCR, and ChIP-PCR analyses are 
listed in Table 4. 
 
2.10 RNA-Sequencing Analysis, DAVID pathway Analysis  
Total RNA was extracted using Trizol from shControl, shEZH2, and shTRIM28 
MCF7 cell lines. RNA-sequencing library preparation used Illumina True-Seq; 
and sequencing was performed by paired-end 150-mer sequencing. Raw reads 
were aligned to human reference genome (hg19) by Tophat v2.0.10 134, reads 
count for each transcript was  obtained by htSeq 135. Differentially expressed 
gene lists were generated using edgeR 136, with adjusted p-value set to be less 
than 0.01. The differentiated gene lists was uploaded into online DAVID 
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functional annotation tool to analyze GO-function and biological biological 
pathways and annotations 137. 
 
2.11 Chromatin Immunoprecipitation (ChIP-PCR), ChIP-Sequencing.  
ChIP-PCR and ChIP-seq are routinely used in our lab 111,133. For chromatin 
immunoprecipitation, MCF7 cells are harvested and then cross-linked for 15 min, 
whereas HMEC cells are cross-linked for 10 minutes. Cells are lyzed with 1 mL 
Cell Lysis Buffer (5mM PIPES pH 8.0, 85mM KCl, 0.5% NP-40, fresh protease 
inhibitors) for 15 minutes. After sonication, the tubes are spun. Supernatant is 
transferred to a new tube to check for fragment size. Lysates are divided and 
diluted using ChIP Lysis Buffer. Immunoprecipitation is performed overnight with 
specific antibodies. The next day, Protein A Sepharose beads (GE Health) are 
incubated with antibody/protein bound complexes for 2 hr at 4°C.  Then, Protein 
A beads are washed and re-suspended and incubated with RNase A for 30 min 
at 37°C and then Protease K for 2 hours at 55°C. The crosslinks are reversed by 
incubating the samples at 65°C overnight. The next day, protein /antibody bound 
DNA fragments are extracted with Phenol/Chloroform. qPCR analyses are 
performed to analyze specific antibody- and protein-bound. DNA was sent out to 
University of Texas MD Anderson Cancer Center science park core sequencing 
facility. ChIP-seq raw reads were aligned to human reference genome (hg19) 
using Bowtie v1.0.0138, allowing up to one mismatch per read. Only uniquely 
mapped reads were kept for downstream analysis. Peaks were called by MACS 
v1.3.7139, using p-value cutoff 1e-8.  
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2.12 In vitro methylation assay 
This method is performed as published in 140. Briefly, recombinant GST-EZH2 (2 
µg) was incubated with various amounts of EZH2 proteins or histone H3 peptides 
in methylation assay buffer (50mM Tris-HCl, pH 8.0, 10% glycerol, 20mM KCl, 5 
mM MgCl2, 1 mM DTT, 1 mM PMSF and 0.1 mM SAM or 3H-labeled SAM [GES 
Health Care]) at 30°C for 4 h. Reactions were stopped by adding SDS-PAGE 
sample buffer, and the methylation status was measured by Western blotting, 
autoradiography. Another simpler method to measure the methylation status is 
liquid scintillation counting.  
 
2.13 IHC staining on TMA 
Immunohistochemistry staining for TRIM28 was performed as before 111. TRIM28 
antibody was incubated with the breast cancer tissue array (Dr. Maciej 
Wiznerowicz’s lab, Poznan University of Medical Sciences), followed by 
extensively wash, and then breast cancer tissue array was incubated with 
secondary antibody. The signal was visualized by adding DAB (3, 3’-
diaminobenzidine). 
 
2.14 CyTOF, Mass Cytometry Sample Processing and Analysis 
MCF7 cells were washed with PBS then disassociated with 0.05% Trypsin 
(Sigma-Aldrich). Following disassociation, cells were washed once with serum 
free DMEM respectively then incubated in serum free media containing 10 µM 5-
Iodouridine (Sigma-Aldrich) at 37°C for 10min. Live/dead cisplatin staining was 
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done according to the methods from [1]. Cells were washed twice with 1%BSA 
(Equitech Bio) in PBS and once with PBS. Cells were fixed with 2% 
paraformaldehyde (PFA) (Sigma-Aldrich) pH 6.9 at room temperature for 15min. 
Following fixation, 1×106 cells/mL were permeabilized with methanol overnight at 
4°C and transferred to -80°C. Following permeabilization, cells were centrifuged 
at 300 x g for 5 minutes to remove methanol, then washed with 1 mL of 1% BSA 
in PBS for each mL of methanol used for permeabilization. Cells were washed 
once with Wash Buffer (0.5% BSA and 0.02% sodium azide in PBS) and 
incubated at a concentration of 4×105 cells/µl with CD24 and CD44 antibodies 
(Fluidigm). After antibody staining cells were washed twice with Wash Buffer, 
once with PBS, then fixed in 0.5mL of 1:2,000191/193 Iridium DNA intercalator 
(Fluidigm) in 4% PFA in PBS at room temp for 30 minutes. Cells were washed 
three times with Wash Buffer and analyzed using a CyTOF mass cytometer 
(Fluidigm). Cells were run at a concentration of 5x106 cells/ml. EQ Four Element 
Calibration Beads (Fluidigm) were added to the samples immediately prior to 
loading into a 96-well plate for autosampler running. Data were normalized based 
on bead signal using the included CyTOF software. Initial data processing and 
gating were performed using FlowJo vX10.0. Beads were gated off of the 
samples and data were gated on singlets, based upon Ir193 and Event Length 
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2.15 Statistical Analyses 
GraphPad Prism6 software (GraphPad Software, Inc.) was used for statistical 
analysis of p-values. The two-tailed paired student t-test was employed to verify 
whether the difference between two groups is significant. P-values < 0.05 were 
considered to be statistically significant. 
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EZH2-RT-F2 GAGACTGGCGAAGAGCTGTTT   
EZH2-RT-R2 GGCATCAGCCTGGCTGTATC           
EZH2-RT-F3 CCCTGACCTCTGTCTTACTTGTGGA 
EZH2-RT-R3 ACGTCAGATGGTGCCAGCAATA    
β-Actin F  TCATGAAGTGTGACGTTGACATCCGT 









HOXA1-F1 TCCTGGAATACCCCATACTTAGCA  
HOXA1-R1 GCCGCCGCAACTGTTG 	  	  	  







AXIN2-ChIP-2-R CACAATGCTAGGGTGGCTTT 	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EZH2, the major H3K27 tri-methyltransferase, is over expressed in multiple 
subtypes of breast cancer; however, whether EZH2 plays an active role in breast 
cancer progression or treatment resistance is unknown. Here, we determined 
EZH2-interacting proteins in MCF7 cells by immunoprecipitation/mass 
spectrometry and detected TRIM28 with a high confidence score.  TRIM28 is a 
transcription co-regulator with an N-terminal tri-partite RING finger, B-boxes and 
a coiled-coil domain (RBCC) and a C-terminal PHD/Bromo domain. Domain 
mapping revealed that the RBCC domain of TRIM28 interacts with EZH2, and 
the pre-SET region (Cysteine-rich domain) of EZH2 interacts with TRIM28. 
Transcriptome profiling and intersection of EZH2- and TRIM28-regulated genes 
indicated co-regulation of differentiation and morphogenesis pathways, as well as 
co-activation of the cytokine-cytokine receptor interaction pathway (CXCR4, 
CXCL12, EGFR, KIT). TRIM28 depletion in MCF7 cells decreased EZH2 
recruitment and CXCR4 gene expression, in parallel with decreased 
mammosphere formation. TRIM28 regulation of EZH2 association with SWI/SNF 
complex might contribute to this process. Collectively these data indicate that 
EZH2 and TRIM28 regulate breast cancer stem cell maintenance by 
transcriptional regulation of CXCR4 gene expression. 
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Introduction: 
 
EZH2 (Enhancer of Zeste Homolog 2), the major, cellular H3K27 tri-
methyltransferase, catalyzes addition of methyl groups at lysine 27 of histone H3 
(H3K27me3) 49.  EZH2 is primarily characterized in repression of transcription, as 
a subunit of the canonical PRC2 complex (Polycomb Repressive Complex 2), 
along with EED, SUZ12, and RBBP4 49. The mammalian PRC2 complex does 
not bind genomic DNA directly in a sequence-specific manner; however, multiple 
DNA-binding proteins, including JARID2 58,59, AEBP2 60 and ATRX 61, are 
implicated in recruitment of PRC2 complex to a variety of target gene loci to 
silence gene expression.  
 
EZH2 is over-expressed in multiple cancers such as prostate, melanoma, 
lymphoma, endometrial and breast, and ectopic expression of EZH2 promotes 
neoplastic transformation of immortalized human breast epithelial cells 141. 
Multiple studies suggest that EZH2 is an attractive therapeutic target, and small 
molecule inhibitors that target its catalytic SET domain 70,72 are now in clinical 
trials for patients with germinal center diffuse large B-cell lymphoma, primary 
mediastinal large B-cell lymphoma (PMBCL) and follicular lymphoma 67,68. EZH2 
has been shown to drive a malignant cancer phenotype in cultured cells derived 
from castration-resistant prostate cancers and, although canonical PRC2 
complex subunits were not required, the EZH2 SET catalytic domain was 
essential 56.   
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 However, the catalytic activity of EZH2 may not be sufficient to account for all 
functions of EZH2 in cancer, and these may prove to be non-responsive to SET-
domain inhibitors142. In contrast to its well-studied role in repression of 
transcription, EZH2 also acts as a transcriptional co-activator of estrogen- and 
WNT-regulated proliferation pathways 66. EZH2 over expression promotes 
expansion of a subpopulation of malignant cells, known as breast cancer 
initiating cells or breast cancer stem cells, by activating RAF1-b-Catenin 
signaling 79 or, as shown elsewhere, by activating NOTCH signaling in an 
H3K27me3-independent manner 80. Additionally, mammary gland-specific 
overexpression of EZH2 in transgenic mice induces hyperplasia of mammary 
epithelium but is not sufficient for tumor initiation and progression 143. Taken 
together, these studies suggest that EZH2 relies on multiple mechanisms to 
intersect with aberrant signaling pathways that play a role in tumorigenesis.  
 
 TRIM28/KAP1 is well studied as a co-repressor of transcription, acting in 
multiple pathways 113,116,120. Like EZH2, TRIM28 does not bind to DNA in a 
sequence-specific manner; it is generally recruited to DNA via sequence-specific 
binding proteins that have KAP1 repressor associated binding (KRAB) domains 
130. TRIM28 expression was previously shown to promote breast cancer 
proliferation and metastatic progression, although the mechanisms were not 
delineated 144. Interestingly, RNAi screens revealed that TRIM28 is required for 
maintenance of mouse embryonic stem cell pluripotency and self-renewal 114, 
which may involve TRIM28 interactions with OCT-4 and subunits of the 
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SWI/SNF2 chromatin remodeling complex, such as Smarcad1, Brg-1 and 
BAF155, to induce embryonic stem cell-specific genes 115.  
 
The subpopulation of cancer stem/progenitor cell is believed to be responsible for 
cancer initiation, cancer progression, and cancer chemotherapy resistance, and 
is still alive after chemotherapy treatment 21,22, and also contributes to one 
hallmark of cancer, heterogeneity 23. Breast cancer stem cell was defined as 
CD44+CD24- population of breast cancer cells 23, Spheroid culture of 
mammosphere was developed as a simple method to measure cancer stem cell 
populations 31,33.  In the studies described here, we show that TRIM28 interacts 
with SWI/SNF and EZH2, in a PRC2-independent manner, to coordinately 
regulate genes with roles in breast stem cell maintenance.  A broader 
understanding of EZH2-mediated regulation and intersection with epigenetic 
regulators in cancers and stem cells is needed to effectively target therapy-
resistant cancers and address the challenges of tumor heterogeneity. 
 
RESULTS 
The pre-SET domain of EZH2 interacts with RBCC domains of TRIM28  
EZH2 promotes neoplastic transformation of breast epithelial cells 141; EZH2 
expression level does not correlate with H3K27me3 level in human breast cancer 
TMA IHC staining (Figure 1 and 2). So, the regulatory mechanisms involved in  
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EZH2-mediated transformation is not well understood. We used MCF7 cells, as a 
model of human estrogen receptor-positive, luminal-type breast cancers that 
comprise a majority of all breast cancers 16, and determined interacting protein 
partners of EZH2. Immunoprecipitation of endogenous EZH2, followed with LC-
MS/MS analysis, identified known members of EZH2 complexes, such as 
SUZ12, EED, PHF1, AEBP2 and DNMT1 58, as well as multiple proteins not 
previously associated with PRC2 (Figure 7 and 8). Among these, co-purified 
proteins with 4 or more peptides identified by LC-MS/MS included factors with 
known functions in binding, remodeling and/or modification of chromatin 
structure, e.g. BRG1, SMARCC2, SMARCA5, BAF180, ARID1A, p300, CHD4 
and TRIM28.  Since EZH2 is primarily associated with repression of transcription, 
we assessed its potential functions as a partner of TRIM28, also known as KAP1 
co-repressor protein 113.  We validated interaction between EZH2 and TRIM28 
proteins by co-immunoprecipitation of Myc-EZH2 and HA-TRIM28 in HEK293T 
cells (Figure 3A and 3B). Endogenous TRIM28, expressed in MCF7 cells, 
likewise interacts with endogenous EZH2, as well as TRIM33, previously 
reported as interacting with TRIM28 110.  Interestingly, although EZH2 associated 
with TRIM28, there was minimal interaction with PRC2 complex member RBBP4 
(Figure 3C).  Antibody enrichment of endogenous EZH2 also co-precipitated 
TRIM28, as well as previously reported PRC2 complex members SUZ12 and 
RBBP4 (Figure 3D). To assess protein complex composition, we performed gel 
filtration chromatography and found two distinct complexes of TRIM28 and  
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RBBP4/EED that co-fractionated with EZH2 (Figure 4A and 10A). Although EED 
and RBBP4 are canonical PRC2 complex members, previously shown as 
essential for EZH2-mediated H3K27 methylation 53-55, the majority of EZH2 in 
MCF7 cells co-fractionated with TRIM28 in a higher molecular weight complex 
(Figure 4A).  
 We determined that the interaction between EZH2 and TRIM28 was direct by 
pull-down assays with bacterially expressed, recombinant proteins MBP-EZH2 
and GST-TRIM28 (Figure 9B). Further, we delineated the domains of interaction 
between EZH2 and TRIM28 by mutation and expression of Flag-EZH2 and HA-
TRIM28 constructs. A series of TRIM28 deletion mutants, which removed the 
RING, RBCC, CC, B-BOX, PHD/bromo domains or the linker region (Figure 5A), 
were co-expressed with Flag-EZH2 in HEK-293T cells for affinity precipitation 
and analysis (Figure 5B).  Removal of the multi-domain RBCC fragment led to 
loss of EZH2-TRIM28 interaction, while separation of the B-boxes and Coiled-
Coil domains decreased binding of EZH2 and TRIM28, showing that multiple 
interactions with EZH2 likely occur across the RBCC domains. Similarly, EZH2 
was serially fragmented as EZH2 A, B, C, D clones from amino- to carboxy-
termini (as illustrated in Figure 6A). Expression and co-immunoprecipitation of 
these mutated forms of EZH2 with full length TRIM28 indicate that the SET 
domain of EZH2 is insufficient for TRIM28 interactions (Figure 6B). These 
results, combined with assays of GST-EZH2 and interaction with endogenous 
TRIM28 (Figure 4B), narrowed binding to the carboxyl-terminal amino acids of 
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385-618 that encompass the pre-SET domain. Thus, RBCC motif of TRIM28 
physically interacts with the pre-SET region of EZH2.  
 
TRIM28 Alters H3K27me3 Distribution 
TRIM28 knockdown did not alter EZH2 expression in MCF7 cells in either protein 
or mRNA level (Figure 11A and B). This ruled out the possibility of TRIM28 
altering EZH2 stability. Next we asked whether TRIM28 regulates H3K27me3 
level. Histone extraction assay demonstrated that TRIM28 depletion does not 
alter the bulk levels of H3K27me3 and H3K4me3 in MCF7 cells (Figure 12). 
Surprisingly, H3K27me3 ChIP-sequencing results in shControl and shTRIM28 
MCF7 cells demonstrated that the peak levels of H3K27me3 appear to be 
dramatically different in response to TRIM28 depletion. To investigate how 
TRIM28 altering H3K27me3 peaks distribution patterns, the differential 
H3K27me3 ChIP-seq peaks between wild type and TRIM28 depletion were 
compared and clustered. Immunofluorescent staining also showed the altered 
H3K27me3 distribution with TRIM28 depletion (Figure 14). In total, the differential 
H3K27me3 peaks (differential peaks >3 folds) between shCtrl and shTRIM28 
cells were divided into two clusters (Figure 13A). Cluster 1 is the increased peak 
heights (>3 folds) of H3K27me3 upon TRIM28 depletion. In contrast, cluster 2 
depicts the decreased H3K27me3 peak heights upon TRIM28 depletion in MCF7 
cells. Progesterone receptor (PGR) (Figure 15A) is an exemplary molecule to 
demonstrate that TRIM28 depletion cause increased H3K27me3 binding on the  
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promoter of PGR, this correlates with decreased PGR gene expression (Figure 
15B). In contrast, in the HOX loci, H3K27me3 binding is depleted in the response 
to TRIM28 depletion (Figure 16A, Figure 18, 19, and 20), H3K27me3 reduction 
on HOXA1 correlates with increased HOX A1 gene expression (Figure 16B). 
Altogether, these data demonstrate that loss of TRIM28 causes improper EZH2 
targeting in MCF7 cells, re-targeting H3K27me3 from HOX loci to different 
genomic loci. Thus, we conclude that TRIM28 is a specificity determinant for 
H3K27me3 localization and function. Examination of global H3K27me3 ChIP-seq 
patterns revealed an unexpected shift to intergenic regions (Figure 13B). These 
data suggested that TRIM28 is required to specify H3K27me3 localization to bind 
its target genes. 
 
DAVID annotation suggests that the cluster 1 related biological processes are ion 
transport, differentiation, development, and cell morphogenesis (Figure 21A); 
KEGG pathway analysis shows that the related pathway is calcium-signaling 
pathway (Figure 21B). Functional analysis of genes from cluster 2 suggests that 
the cluster 2 related biological processes are dicarboxylic acid transport, 
carboxylic acid transport, organic acid transport, L-amino acid transport, and 
amine transport (Figure 21C). The KEGG pathway analysis shows that the 
related pathways are long term depression, tight junction, focal adhesion, 
arrhythmogenic right ventricular cardiomyopathy (ARVC), and ECM-receptor 
interaction (Figure 21D).  
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EZH2 and TRIM28 co-regulate genes associated with differentiation and 
morphogenesis 
To understand the impact of EZH2 and TRIM28 on gene expression in ER-
positive, breast cancer cells, we profiled EZH2- and TRIM28-dependent 
transcriptomes (RNA-sequencing) in MCF7 cells. EZH2 was depleted in shRNA-
stable MCF7 lines at both protein (Figure 27A) and mRNA (Figure 27B) levels. 
Genome wide expression profiling showed that EZH2 activates considerably 
more genes (1063 genes) than it represses (202 genes) in MCF7 cells (Figure 
22A). Biological process analyses (gene ontology or GO functions) revealed that 
EZH2 activates differentiation and morphogenesis-related genes (Figure 22B), 
which are associated by KEGG pathway analysis with ligand-receptor interaction 
molecules and pathways in cancer (Figure 22C). The top biological processes 
(GO functions) of genes repressed by EZH2 are collectively associated with the 
unfolded protein response (Figure 28A).  
 RNA-sequencing of stable shTRIM28 MCF7 cells (Figure 23A) showed that 
TRIM28 depletion led to increased expression of 713 genes and decreased 
expression of 496 genes (Figure 23A). The GO functions of genes activated by 
TRIM28 (repressed in shTRIM28) include cell projection organization, 
morphogenesis, and development (Figure 23A), while those repressed by 
TRIM28 (up-regulated in shTRIM28) are associated with extracellular matrix 
organization, structure, secretion, and adhesion (Figure 29A).  
 To determine whether EZH2 and TRIM28 regulate a shared set of genes in 
MCF7 cells, we intersected EZH2 and TRIM28 transcriptome data. This  
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intersection revealed 134 genes that are differentially expressed in both shEZH2 
and shTRIM28 MCF7 cells (Figure 24A). There are 40 EZH2-activated genes 
that are repressed by TRIM28 (Figure 27D), and only 8 genes are co-repressed 
by both EZH2 and TRIM28 (Figure 27E). Of the 134 differentially regulated 
EZH2/TRIM28 genes, a subset of 77 is down regulated in both shTRIM28 and 
shEZH2 stable cell lines (Figure 28A). Biological process analysis revealed that 
these 77 genes, activated by both TRIM28 and EZH2, share GO functions of cell 
projection, morphogenesis and development (Figure 24B). Interestingly, the 
EZH2/TRIM28 activated gene set is associated with worse overall survival of 
breast cancer patients by TCGA breast cancer patient data analysis (Figure 
25C).  
 
 To identify the directly regulated, target genes of TRIM28 in breast cancer 
cells, we performed TRIM28 ChIP-Seq and integrated these data with 
differentially expressed genes in shTRIM28 MCF7 cells (Figure 32A). Of the 227 
TRIM28 target genes differentially regulated by TRIM28, 16 were activated by 
both TRIM28 and EZH2 (Figure 32A).  Further mining of these data, intersection 
with ENCODE EZH2 ChIP-Seq 145, and validation by real-time RT-PCR of RNA 
isolated from shTRIM28, shEZH2 and shControl MCF7 cells, respectively, 
revealed 7 genes that are directly activated and bound by both EZH2 and 
TRIM28 (Figure 32B, 32C, 32D and 32E).  ChIP-PCR showed that TRIM28 was 
essential for EZH2 association with chromatin at the regulatory regions of these  
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EZH2/TRIM28 co-activated genes, which were previously associated in various 
aspects of cancer promotion, metastasis and stem cells (Figure 32E).  
 
EZH2 and TRIM28 orchestrates a CXCR4 signaling pathway 
KEGG pathway analysis of the coordinately TRIM28/EZH2-regulated 77 genes 
showed that the cytokine-cytokine receptor interaction pathway (CXCR4, 
CXCL12, EGFR, KIT) is the top pathway (Figure 24C). Each TRIM28/EZH2-
regulated gene in this pathway, CXCR4 146,147, CXCL12 146,147, EGFR 148, KIT 20), 
has been implicated as a regulator of cancer stem cells. We examined the gene 
expression mechanisms of EZH2/TRIM28-mediated regulation using CXCR4 as 
our model. Scatter plots of EZH2 and TRIM28 transcriptomes show that CXCR4 
is a highly differentially regulated gene when either EZH2 or TRIM28 is depleted 
in MCF7 cells (Figure 30A and 30B). Real-time RT-PCR of CXCR4 confirmed 
that EZH2 and TRIM28 depletion significantly decreased the mRNA expression 
levels of CXCR4 in MCF7 cells (Figure 30C and 30D). ChIP-PCR analysis of 
EZH2 and TRIM28 binding to chromatin in MCF7 cells showed that both EZH2 
and TRIM28 bind the promoter of the CXCR4 gene (Figure 31A, 32A and B).  
With depletion of TRIM28 in shTRIM28 MCF7 cells, EZH2 recruitment to the 
promoter of CXCR4 was significantly decreased (Figure 32B).  
 Our analysis of EZH2 protein complexes in MCF7 cells showed that TRIM28 
and canonical PRC2 subunits, EED and RBBP4, associated with EZH2 as 
separate entities (Fig. 4A, and 10A).  Interestingly, we found that H3K27me3 
enrichment at the CXCR4 promoter was unchanged when TRIM28 was depleted 
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(Figure 33B), but H3K4me3 and H3K27ac (Figure 33C and D) decrease in 
parallel with TRIM28 and EZH2 binding in shTRIM28 MCF7 cells.  Hence, we 
conclude that TRIM28 recruits EZH2 to the promoter of CXCR4, concomitant 
with activated CXCR4 gene expression, independently of EZH2-mediated 
H3K27me3. 
 
TRIM28 Regulates EZH2 Association with SWI/SNF Complex  
In our analysis of binding partners of EZH2 in MCF7 cell, we identified multiple 
subunits of the SWI/SNF complex: BRG1, SMARCC2, SMARCA5, BAF180, 
ARID1A, as well as p300 (Figure 8A). We determined whether SWI/SNF acted in 
transcriptional activation of CXCR4, as a mechanism of EZH2/TRIM28 activation 
of transcription in breast cancer cells. The association of EZH2 and SWI/SNF 
complex subunits was validated, along with TRIM28 (Figure 34A). Interestingly, 
when TRIM28 was depleted from MCF7 cells (shTRIM28), we observed that 
EZH2 association with the ARID1A subunit of the SWI/SNF association was 
disrupted (Figure 34B). ARID1A is critical for SWI/SNF complex stability, mutated 
in a number of cancers and associated with cellular proliferation and DNA repair 
149,150.  Gel filtration and size fractionation of MCF7 extracts showed that 
SWI/SNF subunits co-elute with TRIM28 and EZH2 as a likely sub-complex of 
proteins associated with EZH2 (Figure 34C). TRIM28 may act as a switch to 
modulate EZH2 and SWI/SNF association and regulate EZH2-activated genes, 
such as CXCR4.  SWI/SNF chromatin remodeling complexes function in 
positioning, sliding, exchanging or evicting nucleosomes, which impact chromatin  
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structure-dependent processes, including transcription, replication and DNA 
repair essential for cellular homeostasis 151. We analyzed histone H3 enrichment 
by ChIP-PCR as a gross assessment of nucleosome occupancy across the sites 
of TRIM28/EZH2 interactions at their differentially regulated target genes in 
MCF7 cells (Figure 33A). These findings suggest that TRIM28/EZH2-mediated 
interactions with SWI/SNF complexes alter chromatin structure of their shared, 
activated target genes. 
 
TRIM28 Regulates MCF7 Mammosphere Formation and Stem Cell 
Maintenance 
Previous studies of tumor-derived cells and mouse models showed that the 
PRC2 complex has opposing functions to the SWI/SNF complex in oncogenic 
transformation and cancer-associated stem cells 152. How EZH2 may function 
with regards to SWI/SNF in non-PRC2 dependent activities, as we define here in 
MCF7 cells, is unknown. Given previous association of SWI/SNF with cancer 
stem cells and our finding that CXCR4, a marker of cancer stem cells, is a target 
of EZH2/TRIM28 activation, we used MCF7 sphere-forming or mammosphere 
assays 31,153, as a surrogate for cancer stem cell assessment and to determine if 
a TRIM28/EZH2 axis had a role in breast stem cell maintenance.  
 First, we assessed whether EZH2 and/or TRIM28 played roles in 
mammosphere formation using shControl, shEZH2 and shTRIM28 MCF7 cells 
(Figure 35A). The number of mammospheres formed was significantly decreased 
by depletion of either EZH2 (Figure 35A) or TRIM28 (Figure 36A). MCF7 
mammosphere numbers were greatly reduced in shTRIM28 cells and rescued by 
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TRIM28 expression (Figure 36A and B). To further assess the effects of varying 
levels of TRIM28, we relied on a different vector and clone selection method to 
over express TRIM28 in MCF7 cells and saw increased efficiency of 
mammosphere formation, as well as increases in size of the formed 
mammospheres (Figure 37A). These data confirm previous reports that EZH2 
plays a role in maintenance of breast cancer stem cells 79,80, using this assay 
system, and suggest that TRIM28 likewise regulates MCF7 mammosphere 
formation and stem cell maintenance. 
Breast stem cell populations are characterized by cell surface marker expression 
patterns of CD44+ and CD24- or low 23,33.  We determined levels of these  
indicators by mass cytometry, or CyTOF (Fluidigm) 154, of MCF7 cells with 
ectopic expression of TRIM28 or eGFP (Figure 37C). The population of 
CD44+/CD24- cells in TRIM28 overexpressing MCF7 cells is two-fold greater than 
control MCF7 plus eGFP cells, (Figure 37C). Further rescue assays of ectopic  
eGFP, TRIM28 and EZH2 expression in shControl and shTRIM28, showed that  
TRIM28 and EZH2 are epistatic in mammosphere formation (Figigure 38A).  
Overexpression of EZH2 was sufficient for significant rescue of mammosphere 
formation and required EZH2/TRIM28 interaction domain, even when TRIM28  
was depleted.  A pre-SET domain deletion mutant EZH2 construct failed to 
rescue EZH2 dependant mammosphere formation (Figure 38C), which indicates 
that the interaction of TRIM28 with EZH2 is critical for EZH2 mediated 
mammosphere formation. Full length TRIM28 failed to rescue EZH2 dependant 
mammosphere formation (Figure 38C), which indicates that TRIM28 is upstream 
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of EZH2 (Figure 38C). Taken together with our global expression analyses, 
which indicated that TRIM28 and EZH2 coordinately regulated expression of 
genes with biological functions in differentiation and morphogenesis (Figure 25B), 
our findings support a role for TRIM28 in facilitating EZH2-mediated functions in 
stem cell maintenance. 
 
pS473/824 TRIM28 does not interact with EZH2 in breast cancer cells 
To investigate how the phosphorylation of TRIM28 affects its interaction with 
EZH2. Surprisingly, S473/824TRIM28 showed diminished interaction with EZH2 
(Figure 42). In other words, S473, S824 phosphorylation interferes EZH2 
interaction with TRIM28. In addition, SA mutants of TRIM28 show huge 
increased amount of binding with EZH2 compared with wild type TRIM28 (Figure 
43).   
 
DISCUSSION: 
Here we report that the pre-SET domain of EZH2 interacts with TRIM28 in a 
RBCC domain dependent manner in breast cancer cells. Further study indicates 
that TRIM28 regulates EZH2 association with SWI/SNF complex in breast cancer 
cells. The interaction of TRIM28 with EZH2 may contribute to breast cancer stem 
cell phenotype maintenance through transcriptionally activating CXCR4 cancer 
stem cell signaling pathway. So, targeting the highly expressed EZH2 in breast 
cancer might provide a valuable strategy to overcome resistance of breast 
cancer chemotherapy by eliminating breast cancer stem cell. The deeper 
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understanding of EZH2 regulation by further study is of interest for breast cancer 
patients. 
 
The newly identified interaction of TRIM28 with EZH2 might contribute to the 
polycomb-independent role of EZH2 in breast cancer, and this polycomb-
independent role of EZH2 was also reported in prostate cancer 155. The specific 
region of EZH2 interacting with TRIM28 is the pre-SET domain region (containing 
CXC domain); the pre-SET domain region of EZH2 was reported to direct SET 
domain activity in drosophila156.  In mammal study, the pre-SET domain interacts 
with AEBP2 157, SUZ12 157, and PAF 158. Historically, the name of “CXC domain” 
was originally coined to refer to the pre-SET motif of EZH2159 in drosophila, but 
now, the pre-SET domain of EZH2 refers to more than CXC domain 158. The 
TRIM28 regulation of pre-SET domain (CXC) region of EZH2 in mammalian 
system suggests that TRIM28 might also direct SET domain activity, switching 
EZH2’s affinity between histone substrate and non-histone substrates. Thus, 
targeting EZH2/TRIM28 interaction could be a better approach to dampen breast 
cancer progression than targeting SET domain. The current EZH2 inhibitors 
(Epizeme, GSK, etc) were designed to target SET domain, Stuart Orkin‘s 
antiproliferative experiments using GSK-126 on MDA-MB-231 cells appear no 
effect at all142. This knowledge in combination with our study here indicates that 
an effective EZH2 inhibitor design should target the pre-SET domain of EZH2. 
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Functionally, through transcriptome study, TRIM28 mediated EZH2 activity was 
pinpointed to maintenance the breast cancer stem cells phenotype via 
transactivating CXCR4 signaling pathway. We report to identify CXCR4/CXCL12 
pathway as EZH2’s H3K27me3 independent targets. TRIM28 also directly 
targets CXCR4/CXCL12 pathway through regulating recruitment of EZH2 onto 
the CXCR4 promoter. Whereas, a very recent publication80 of investigating 
mechanism of EZH2 expanding breast cancer stem cell discovered NOTCH 
signaling as EZH2’s H3K27me3 independent targets. The possible reason of this 
discrepancy is probably due to the technical limitation of specific stem cell 
signaling focused PCR array this group employed in this specific study, while we 
used RNA-sequencing with better coverage of the whole genome.  
 
This is the very first time to report the function of TRIM28 in breast cancer stem 
cell biology. There are at least two publications highlighted that TRIM28 
implicated in embryonic stem cell biology114,115. In general, cancer stem cell 
tends to phenocopy embryonic stem cell, if we link SOX2 from stem cell to 
cancer stem cell 160. Additionally, our data indicate that mutant EZH2 of deleting 
the interaction domain with TRIM28 shows very limited capacity to form 
mammosphere.  This data show that EZH2/TRIM28 interaction is critical for 
breast cancer stem cell maintenance. Thus, targeting EZH2/TRIM28 interaction 
is a very useful approach to dampen breast cancer progression. Breast cancer 
stem cell represents the novel direction of drug resistant breast cancer therapy 
development 20-22. The newly identified breast cancer stem cell regulatory axis 
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could be a potential therapeutic target. Thus, this study brings unparalleled value 
to the community.  
 
Moreover, our data indicates that TRIM28 maintains breast cancer stem cell 
population. Previously, TRIM28 was published to promote breast cancer 
proliferation and metastatic progression 144, we did invasion and metastasis 
assays in our lab, the TRIM28 mediated effect of metastatic progression is 
relatively marginal in MCF7 cells. However, Douglas Cress published that 
TRIM28 suppress MDA-MB-231 cells proliferation 161, and proposed a model that 
TRIM28 is a tumor suppressor in early transformation stages, but in later stages 
it functions as an oncogene in lung cancer 162. In breast cancer, It is also possible 
that the proliferation regulation of TRIM28 could be cell line dependent effect, or 
post-translational modification dependent effect of TRIM28 127. These questions 
can be answered by mouse genetics methods, and further biochemical 
characterization of TRIM28 protein in vivo. And another question still remains 
whether TRIM28 mediated breast cancer promotion are dependent on the 
expansion, differentiation of breast cancer stem cell or some other mechanisms?  
 
EZH2 was proposed to contribute to tumor progression via its H3K27me3 
dependent transcriptional repressive program for a long time 163,164. But there are 
arguments that the oncogenic function of EZH2 is independent of H3K27me3165. 
We observed that TRIM28 regulates cancer stem cell stemness by directly 
regulating CXCR4 signaling in an H3K27me3 independent manner. This 
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indicates the possible existence of non-histone substrates of EZH2 as a 
methyltransferase in breast cancer 165, this concept is also in agreement with 
other types of cancers, such as castration resistant prostate cancer56, 
glioblastoma 166. This study is the further extension of some of the previous 
publications revealing the transactivation or polycomb-independent role of EZH2 
in breast cancer66,80, prostate cancer56, and potentially other types of cancers.  
 
Our transcriptome study indicates that a set of 134 genes is co-regulated by both 
EZH2 and TRIM28. Among these gene list, 77 genes are co-activated genes, 
these 77 genes enriched cytokine cytokine receptor interaction pathway 137, 
which is implicated in regulating cancer stem cell stemness 146. Some of genes in 
these 77 genes are not well studied in either stem cell, or cancer biology yet; it is 
very likely there are more genes in this list that are uncharacterized regulatory 
proteins/factors for breast cancer stem cell self-renewal and differentiation, or 
even other types of cancer stem cells.  
 
In summary, TRIM28 interacts with EZH2 to regulate breast cancer stem cell 
maintenance. TRIM28 and EZH2 axis contributes to activation of CXCR4 gene 
expression, and then render to be an effective therapeutic target for optimized 
effective EZH2 therapy in breast cancer, and other types of breast cancer. 
  
  
Copyright (c) 2015 Jing Li, All rights reserved
























Copyright (c) 2015 Jing Li, All rights reserved
	   113	  
CHAPTER IV: TRIM28 Phosphorylation Switch Regulates Breast Cancer 
Cell Proliferation  
Abstract:  
TRIM28 (KAP1, TIF1β) is broadly associated with transcription repression, 
facultative heterochromatin functions, embryonic stem cell renewal and, more 
recently, breast cancer metastasis. TRIM28’s functions in breast cancer 
progression remain largely unclear. TRIM28 is overexpressed in HMEC model of 
breast cancer progression; interestingly, TRIM28 is heavily phosphorylated 
(pS824/pS473) in aggressive breast cancer cells. Furthermore, ectopic 
expression of TRIM28 WT and phosphorylation defective form in HMEC cells 
indicates that TRIM28 promotes cell proliferation in a phosphorylation dependent 
manner. Genome-wide TRIM28 binding profile analysis unveils a novel binding 
motif, highly similar with TCF4 motif. The promoter of AXIN2 encompass one of 
this kind binding motif of TRIM28, is a direct transcriptional target of TRIM28. 
TRIM28 specifically express in the epithelial cells of mammary gland, but not 
myoepithelial cells. Collectively, we demonstrated a mechanism of regulation of 
breast cancer cell proliferation by TRIM28 in a phosphorylation dependent 
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Introduction:   
TRIM28 (KAP1, KAP-1, TIF1β) connects heterochromatin and euchromatin, is 
one of known facultative heterochromatin proteins 107,167, and structurally belongs 
to tripartite motif superfamily. The tripartite motif is composed of a RING finger 
followed by two B-boxes and a coiled-coil domain, also called RBCC motif; 
TRIM28’s C-terminal is composed of a bi-partite motif encompassing a PHD 
finger and a Bromo domain. TRIM28 was known as a universal transcription 
corepressor protein by interacting with the Kruppel associated box (KRAB)-
domain containing zinc finger proteins 102,103. TRIM28 binds and co-localizes with 
HP1 (heterochromatin protein 1) through a well-defined peptide motif, PxVxL. 
HP1 reads H3K9me3 (a repressive histone marker) with its chromo domain to 
play a pivotal role in heterochromatin mediated gene silencing 104. TRIM28 
depletion leads to lower level of global H3K9me3 105,106. TRIM28 binds and 
recruits SETDB1 complex to H3K9me3 genomic sites mediating heterochromatin 
silencing 107.  TRIM28 is phosphorylated at S824 by ATM/ATR to form foci within 
DNA double strand break sites 122, and phosphorylated at S473 by CHK1/2 
during DNA repair 123 in the response of DNA damage. Phosphorylation of 
TRIM28 might affect the ability of TRIM28 to condense chromatin 122,168. Both 
Serine 473 and 824 residuals phosphorylation play an important role in DNA 
damage/repair pathway. TRIM28 was recently reported to promote proliferation 
and metastatic progression of breast cancer cells 169, and acting as an oncogenic 
protein. However, the exact role of TRIM28 in breast cancer progression remains 
largely unclear.  
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In the study described herein, we document that TRIM28 exhibits a novel-binding 
motif in breast cancer cells, which is distinct from its counterpart in embryonic 
stem cell; TRIM28 is overexpressed in HMEC model of breast cancer 
progression; interestingly, TRIM28 is heavily phosphorylated (pS824/pS473) in 
aggressive breast cancer cells. Additionally, ectopic TRIM28 expression in 
HMEC cells promotes cell proliferation in a phosphorylation dependent manner.  
Further analysis unveiled that phosphorylated TRIM28 (pS824/pS473) is required 
for breast cancer stem cell maintenance, suggesting a phosphorylation 




pS473/824 TRIM28 is overexpressed in breast cancer cells 
To determine TRIM28 expression profiles in five different subtypes of breast 
cancer cells, we profiled proteins expression level of TRIM28 in HMEC system. 
Surprisingly, TRIM28 is overexpressed in HMEC systems (Figure 44A, B, and C). 
mRNA level of TRIM28 also slightly increased along with breast cancer 
progression (Figure 44D). Interestingly, the total TRIM28 protein expression level 
between 184A1 and AE003 HMEC remains the same (Figure 44A, B, and C), 
however, the dramatic difference of S473/824 TRIM28 expression between 
184A1 and AE003 HMEC cells is observed, which indicates a potential 
oncogenic role of S473/824TRIM28 in breast cancer. Based on their expression  
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profile, we designate 184A1 HMEC cells as pS824 low /pS473low184A1-HMEC 
cells; AE003 HMEC cells as pS824high /pS473highAE003-HMEC cells.  
 
TRIM28 negatively regulates breast cancer growth in a phosphorylation 
dependent manner 
These data raises a question whether phosphorylation of TRIM28 might play a 
pivotal role in breast cancer progression. To investigate the role of 
phosphorylated form of TRIM28, first, we knocked down TRIM28 in pS824 low 
/pS473low184A1-HMEC cells to test their proliferation and colony formation. As 
expected, TRIM28 negatively regulate pS824 low /pS473low184A1-HMEC cells 
proliferation by counting cell numbers (Figure 45D). TRIM28 knockdown 
efficiency was shown (Figure 45A). Colony formation assay also indicates that 
TRIM28 significantly inhibits HMEC cell colony formation (Figure 45B, C). The 
data are in agreement with a previous research report 170. So, we decided to test 
this result in another HMEC cell line, AE003 that represents an advanced stage 
of breast cancer with higher level of pS824/pS473 TRIM28. TRIM28 knockdown 
efficiency was shown (Figure 46A). Surprisingly, there is no growth effect for  
shTRIM28 pS824high /pS473highAE003-HMEC cells (Figure 46B, C, Figure 46D). 
Thus, these data demonstrates that there is phosphorylation-dependent 
proliferation phenotype of TRIM28. This further suggests a phosphorylation 
dependent proliferation effect of TRIM28 in breast cancer cells.  
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To further validate the phosphorylation-dependent proliferation phenotype of 
TRIM28, TRIM28 wild type, S473A, S824A, and double serine alanine mutants 
were transfected into AE003 cells, a dramatic proliferation phenotype was 
observed (Figure 47B). The transfection efficiency was verified in figure 47B, 
S824A and double SA mutants exhibited lower phosphorylation levels of TRIM28 
when they were detected with phosphorylation specific antibodies (Figure 47B). 
Thus, these data demonstrated that there is phosphorylation-dependent 
proliferation phenotype of TRIM28 in breast cancer.  
 
TRIM28 is specifically expressed in the epithelial cells, but not in the 
myoepithelial cells 
To determine the expression profile of TRIM28 in human breast cancer patients, 
IHC staining of human normal breast tissues indicates that TRIM28 is mainly 
expressed in the epithelial cells, but not in the myoepithelial cells (Fig 48A). For 
luminal A, luminal B, HER2 positive, and basal type of breast cancers, TRIM28 
express on both of the epithelial and myoepithelial cells in human breast cancer 
patients. This suggests that TRIM28 not only regulates myoepithelial lineage in 
normal mammary tissue, but also promotes bi-lineage identify in breast cancer 
tissues. TRIM28 deregulation in breast cancer might play a critical role in 
epithelial and myoepithelial lineages transition. 
 
TRIM28 and Phosphorylation-TRIM28 level increases in malignant types of 
breast cancer 
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To rule out the possibility that this is cell line dependent effect, profiling the 
expression of TRIM28 in human established breast cancer cell lines that 
represent five subtypes of breast cancers reveals that TRIM28 express higher in 
breast cancer compared with normal cell line. However, the overall survival of 
breast cancer patients with deregulated TRIM28 show no difference, which 
suggests that post-translational modification of TRIM28 might be the functional 
form to contribute to breast cancer progression, specifically S473/824 TRIM28 
phosphorylation. Surprisingly, S473/824 TRIM28 is overexpressed in high 
malignant breast cancer cell lines, especially in basal/triple negative breast 
cancer cell lines (Figure 49A, B, and C). 
 
Phosphorylation of TRIM28 is required for regulation of cancer stem cell 
fate 
To understand whether the phosphorylation dependent of breast cancer cell 
proliferation TRIM28 is due to phosphorylation dependent regulation of breast 
cancer stem cell fate, we overexpressed SA and SD mutants of TRIM28  
in shTRIM28 MCF7 cells and performed the mammosphere assay. As expected, 
SA mutants of TRIM28 could not rescue shTRIM28 phenotype (Figure 50A, and 
B), but SD mutants of TRIM28 perfectly rescued shTRIM28 mediated 
mammosphere size decrease  (Figure 50A, and B). This data indicate that 
phosphorylation of TRIM28 is required for maintenance of breast cancer stem 
cell. Thus, we conclude that the phosphorylation dependent of breast cancer cell 
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proliferation TRIM28 is due to phosphorylation dependent regulation of breast 
cancer stem cell fate. 
 
TRIM28 exhibits a Novel TCF4 Binding Motif in breast cancer MCF7 cells 
In order to investigate the mechanism and functions of TRIM28-mediated 
proliferation regulation in human breast cancer cells, we performed TRIM28-
specific chromatin immunoprecipitation with deep sequencing (ChIP-seq) in 
MCF7 cells, because MCF7 cells express very high level of TRIM28 (Figure 49A, 
B, and C). These analyses revealed 21274 TRIM28-bound peaks in MCF7 cells 
(Figure 51A). GO term analysis demonstrate that TRIM28 bound genes exhibits 
a prominent role of positive regulation of epithelial to mesenchymal transition 
(EMT) in breast cancer cells (Figure 53B), as well as transcription (Figure 53B), 
RNA metabolic process.  
 
To further understand the global binding distribution of TRIM28, we did TRIM28 
global binding profiles comparison between human embryonic stem cells 171 and 
breast cancer MCF7 cells. The global binding profiles comparison reveals that 
the TSS (+/-3KB) binding sites is robustly increased from 4.67 percent to 14.35 
percent (Figure 51B), nearly three folds enrichment to the transcription start site, 
as TRIM28 binding profile from undifferentiated cells (hESC) to differentiated 
cells (MCF7). This suggests that a subset of genes is gaining TRIM28 binding on 
their promoter, which might correlate with TRIM28 mediated transcriptional 
repression/activation. 
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We next compared TRIM28 global binding motif between hESC and MCF7 cells. 
In details, TRIM28 ChIP-sequencing in H1 human embryonic stem cell (a public 
dataset 171) exhibits 20026 unique TRIM28 bound peaks with our re-analysis of 
the public dataset 171; whereas TRIM28 ChIP-sequecencing in breast cancer 
MCF7 cells reveals 14745 unique TRIM28 bound peaks. The integration of 
TRIM28 ChIP-sequencing between embryonic stem cell and MCF7 cells yields 
only 3455 peaks shared between hESC and MCF7 cells. This suggests that 
TRIM28 global binding profile and potential transcriptional program is 
dramatically different between hESC and MCF7 cells.  
Copyright (c) 2015 Jing Li, All rights reserved
	   134	  
 
Copyright (c) 2015 Jing Li, All rights reserved
	   135	  
 
Enriched motif analysis revealed the different binding mechanisms of TRIM28 in 
hESC and MCF7 cells. The ChIP-seq we performed in MCF7 cells unveils a 
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TCF4 binding motif, RBP-J and Stat4 binding motif. Whereas, the ChIP-seq data 
re-analysis from H1 hESC cells reveals that the top TRIM28 binding motif is 
RBP-J and Stat4 binding motif (Figure 52A). No TCF4 binding motif is enriched in 
human ES cells indicated that TCF4 motif is breast cancer specific (Figure 52A), 
about 2844 out of 21274 TRIM28 bound peaks (>10%) enriched with TCF4 
binding motif (Figure 52A). This demonstrated a potential unique interplay 
between TRIM28 and TCF4, a sequence specific transcription factor containing a 
basic helix-loop-helix (bHLH) 172, and potentially Wnt signaling in breast cancer 
cells. Thus, the different binding profile between hESC and MCF7 suggests that 
TRIM28 may be recruited to chromatin by different DNA-binding factors in breast 
cancer cells than human embryonic stem cells. In other words, TRIM28 controls 
a breast cancer specific subset of genes that are 2844 peaks TRIM28 bound, 
enriched with TCF4 motif.  
 
TRIM28 direct target genes in breast cancer is associated with Growth, 
Morphogenesis 
We examined TRIM28 directly targeted genes list that was generated by 
integrating TRIM28 ChIP-seq and RNA-seq in MCF7 cells. TRIM28 direct target 
genes were firstly analyzed in GREAT online annotation tool 173, the mouse 
phenotype shows “increased growth rate” (Figure 53A).  This suggests that the 
main function of TRIM28 in breast cancer cells might be involved in cell growth, 
proliferation. Further, functional annotation study revealed that the function of 
TRIM28 activated target genes is cell projection organization, morphogenesis, 
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and axonogenesis (Figure 53E). The function of TRIM28 repressed target genes 
is associated with transcription regulations (Figure 53F), related to ABC 
transporters (Figure 54B).  Surprisingly, KEGG pathway analysis shows that 
TRIM28 activated target genes are associated with Hedgehog signaling pathway, 
which were linked with breast cancer stemness 174 (Figure 54A).  
 
Genome-wide Binding Profile of TRIM28 Highly Correlates with H3K9me3 
TRIM28 was previously known to correlate with histone marker H3K9me3. But 
there is no direct evidence whether TRIM28 global binding profile still correlates 
with H3K9me3 in breast cancer cells. The correlation analysis by comparing 
TRIM28 ChIP-seq of MCF7 cells with H3K9me3 ChIP-seq demonstrated that 
TRIM28 binding events highly correlate with H3K9me3 (Figure 55A), but not 
H3K9me2 (Figure 55B), H3K9ac (Figure 55C), H3K27me3 (Figure 55D), and 
H3K27ac (Figure 55E). In conclusion, this data indicates that TRIM28 binding 
events specifically correlate with H3K9me3 in breast cancer, not other kinds of 
histone modifications.  
 
AXIN2 is a direct target gene of TRIM28 in breast cancer cells 
Binding motif analysis of TRIM28 ChIP-seq unveils a unique TCF4 binding motif 
in breast cancer cells (Figure 52A), which suggests a potential direct 
transcriptional activation/repression role of TRIM28 on a subset of TRIM28 
bound genes containing TCF4 binding motif. A gene that encompass TCF4 
binding motif could be a direct target gene of TRIM28, may implicate in breast 
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cancer tumorigenesis. To identify transcriptional target genes of TRIM28 in 
breast cancer cells, we examined TRIM28 directly targeted genes list that was 
generated by integrating TRIM28 ChIP-seq and RNA-seq in MCF7 cells. AXIN2 
was the top hit (Figure 56A), since 1) it is a Wnt signaling target gene; 2) 
contains a TCF4 binding motif we identified on the promoter region (+/-3KB of 
TSS). This suggests that TRIM28 might transcriptionally regulate AXIN2 gene 
expression on a direct transcriptional level.  
 
To further test whether AXIN2 is a transcriptional target gene of TRIM28, AXIN2 
mRNA level was examined in the TRIM28 depleted cells; it suggests that AXIN2 
gene expression was reduced upon TRIM28 depletion. (Figure 56B) TRIM28 
ChIP was performed on the promoter of AXIN2. Data indicate that TRIM28 binds 
on the promoter of AXIN2 (Figure 56C). To understand the histone modification 
status of TRIM28 mediated AXIN2 gene expression, we examined the 
H3K27me3 ChIP-seq profiles in both shCtrl and shTRIM28 MCF7 cells (Figure 
56A), we found a decreased level of H3K27me3 on the promoter region of 
AXIN2, ChIP-PCR was performed to verify the reduced H3K27me3 level on the 
promoter of AXIN2 upon TRIM28 depletion (Figure 56D). Thus, we conclude that 
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In this paper, we presented that epithelial cell specifically expressed TRIM28 
promotes breast cancer cell proliferation in a phosphorylation dependent manner. 
Using a unique HMEC system 175, we demonstrated that TRIM28 and 
phosphorylation of TRIM28 is overexpressed in malignant types of breast cancer, 
TRIM28 depletion promotes pS824 low /pS473low184A1-HMEC cell proliferation, 
but no effect for pS824 high /pS473highAE003-HMEC cells. Ectopic expression of 
TRIM28 phosphorylation defective SA mutants inhibited breast cancer cell 
proliferation. We identified a novel unique TRIM28 binding motif in breast cancer 
cells, showing high similarity with TCF4 binding motif. Then, we identified that 
AXIN2 contains TCF4 binding motif and serve as a directly transcriptional target 
gene of TRIM28 in breast cancer cells. It is very likely that the tumor regulating 
effect of TRIM28 is context dependent. Our unique HMEC system 175 contributes 
to this interesting question related to different contexts. 
  
The investigation of overcoming resistance of breast cancer treatment is in 
extremely high demand. Epigenetics has emerged as intriguing field to possess a 
lot of opportunities to overcome treating difficult breast cancer patients. Deeper 
understanding of cancer or breast cancer specific epigenetics is a key step to 
discover novel therapies. TRIM28 was implicated in embryonic stem cell 114 and 
cancers169,176. Priscilla Turelli & Didier Trono reported 171 that more than 57,000 
TRIM28 peaks were called in hESC, close to three-quarters of which were on 
EREs (endogenous retroelements), which is in line with our data of Figure 1B. 
Though we used a different peak calling approach, the TRIM28 global binding 
Copyright (c) 2015 Jing Li, All rights reserved
	   140	  
profile is similar, since we called 23481 TRIM28 binding peaks in H1 hESC cells, 
15133 peaks are in the intergenic region. They failed to present the rest of over 
one-quart of TRIM28 bound peaks. So, at least one-quarter of TRIM28 bound 
peaks are regulating non-ERE gene expression in hES cells. Our re-analysis of 
the TRIM28 bound peaks in hESC indicates that TRIM28 might regulate NOTCH 
signaling pathway not only in hESC, but also in breast cancer cells. The shared 
regulatory characteristic of NOTCH signaling in both model cell system suggest 
the potential critical role of TRIM28 in connecting NOTCH signaling with breast 
cancer stem cells. 
 
Our reanalysis of published TRIM28 ChIP-seq data demonstrated that TRIM28 
binds with RBP-J motif in human ES cells.  In contrast, TRIM28 exhibits a novel 
unique TCF4 binding motif in breast cancer cells on top of RBP-J motif, which 
suggests a more profound role of TRIM28 in breast cancer, which might involve 
in Wnt signaling, and NOTCH signaling. The role of TRIM28 in breast cancer 
remains largely unclear.  Previous publications showed the controversial role of 
TRIM28 in cancer progression in a context dependent manner. TRIM28 acts as 
an oncogenic protein to promote breast cancer progression 169. TRIM28 global 
binding profiling ChIP-sequencing revealed TRIM28 has 2844 peaks out of total 
21274 TRIM28 binding peaks sharing similarity with TCF4 binding motif, implying 
its role in mediating Wnt signaling in breast cancer.  
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Similarly, there are 2698 TRIM28 bound peaks that share binding motif with 
RBP-J binding motif, which suggests that TRIM28 might also have a role in 
NOTCH signaling pathway in breast cancer cells, since RBP-J is a major Notch 
effector protein 177. Notch signaling pathway is prominent in the field of cancer 
biology and cancer stem cell, emerging as an attractive target of cancer therapy 
178. This implies that TRIM28 might deeply involve in NOTCH signaling in breast 
cancer, maybe in other types of cancer as well. The novel TRIM28 binding motif 
exhibits the tremendous interests to the breast cancer field, because of its high 
similarity with RBP-J motif, a relatively well studies transcription factor. RBP-J 
remains as a transcriptional repressor by recruiting chromatin remodelers in the 
absence of NOTCH signaling, it transform into a transcriptional activator through 
forming a complex with NOTCH1 in the presence of NOTCH signaling.  
 
It was reported that Wnt/β-catenin is a central downstream effector of Notch 
signaling in cardiac progenitor differentiation 179, in this chapter, we reported that 
TRIM28 transcriptionally activates AXIN2 gene expression, which is a target 
gene of WNT signaling pathway. So, it is possible that TRIM28 activates AXIN2 
through binding TCF4 binding motif, since there are multiple TCF4 binding motif 
around the promoter region of AXIN2. This question might need to be further 
validated in the future.  
 
The deeper understanding of TRIM28 regulation by further study is of interest for 
cancer patients. This research will set a fundamental stage for instructing 
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TRIM28 inhibitor development against chemotherapy resistant breast cancer.  
TRIM28 inhibitor could be a promising anti-breast cancer drug, which may still 
need extensive research and develop in the academia and pharmaceutical 
industry.  
 
Therapeutically, one of the most obvious questions is which domain of TRIM28 
needs to be targeted, considering design a TRIM28 inhibitor. The inhibition of 
Bromo domain of TRIM28 is particularly interesting because bromo domain 
inhibitors are in the hot trend of the whole pharmaceutical industry. However, 
whether it is a real case for TRIM28 remains unknown. The RBCC motif has a lot 
of impact for cells in various aspects, first, it could act as an E3 ubiquitin ligase 
collaborate with MAGE A3/A6 to degrade p53132,180, and collaborate with MAGE 
A3/A6 to degrade AMPK in a cancer specific manner since MAGE proteins are X 
chromosome specific, be turned on in cancer cells181, second, it could serve as a 
sumo E3 ligase to add sumo moiety onto IRF7 182, NPM1183, and Vps34 184. 
Clear understanding of this mechanism is prerequisite to develop a rational 
TRIM28 inhibitor. The breast cancer, mammary gland specific feature of TRIM28 
also needs to be understood in order to design a TRIM28 inhibitor for breast 
cancer. 
 
It is extremely intriguing that TRIM28 express in the epithelial cells, but not in the 
myoepithelial cells indicated by IHC staining of human normal breast, but 
express at both myoepithelial and epithelial cells in luminal A, luminal B, HER2, 
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Basal type breast cancers; since myoepithelial cells is reported to originate from 
epithelial cells185,186, the unique expression pattern of TRIM28 suggests that 
TRIM28 might play an important role in epithelial cells’ differentiation into 
myoepithelial cells. In addition, basal lineage breast cancer is derived from 
myoepithelial cells 14,187; this raises a possibility that TRIM28 might involve in the 
programming of luminal type breast cancer into basal type breast cancer. This 
suggests that TRIM28 might only regulate myoepithelial lineage in normal 
mammary tissue, but promotes bi-lineage identify in breast cancer tissues.  
 
Phosphorylated form of TRIM28 (pS824) is involved in mouse embryonic stem 
cell self-renewal 115. The mechanism is that pS824 TRIM28 specifically activates 
pluripotent genes. However, I could not repeat this data in breast cancer cells, 
which suggests that the significant differences between embryonic stem cells and 
breast cancer cells. This is in line with our genome wide TRIM28 binding profiles 
comparison data in Figure 51. In the future study, it would be very interesting 
whether and how TRIM28 coordinates Wnt and Notch signaling as a chromatin 
platform, because TRIM28 binds with both TCF4 motif and RBP-J motif.   
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In this dissertation, we discovered that EZH2 interact with TRIM28 in a RBCC 
domain dependent manner in breast cancer cells. Further study indicates that 
TRIM28 mediates EZH2 recruitment on the promoter of CXCR4, one of the 
breast cancer stem cell marker genes. This interaction of TRIM28 with EZH2 
may contribute to breast cancer stem cell phenotype through collaboratively 
transcriptional activating CXCR4 cancer stem cell signaling pathway. Targeting 
the highly expressed EZH2 in breast cancer might provide a useful strategy to 
overcome chemotherapy resistance of breast cancer. Collectively, our data 
demonstrated that targeting EZH2/TRIM28 interaction is a better approach to 
dampen breast cancer progression (Figure 59).  
 
The potential link of cancer epigenetics with cancer immunotherapy in the 
perspective of EZH2 study 
EZH2 is known to promote cancer progression, invasion, and cancer stem cell 
maintenance, thus serve as a promising therapeutic target for various types of 
cancer. However, EZH2 is also essential for immune system homeostasis. So, 
the administration of EZH2 into cancer patients has the potential to further inhibit 
the weakened cancer immune system of patients 188, then harm the patients’ 
overall survival and quality of life. Thus deeper understanding of EZH2 inhibition 
considering not only epigenetics but tumor surrounding immune system is 
required for the future.  
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The transcriptional co-activator role of EZH2 in breast cancer 
Previously, EZH2 was believed to contribute to tumor progression via its 
H3K27me3 dependent transcriptional repressive program for a fairly long time 
163. But, most recently, the oncogenic function of EZH2 in castrate resistant 
prostate cancer is independent of H3K27me3 165. We observed the similar results 
of inconsistent correlation of EZH2 and H3K27me3 levels in breast cancer in 
human breast cancer tissue array. This suggests the potential existence of non-
histone substrates of EZH2 as a lysine methyltransferase in breast cancer. This 
is the further validation of some of the previous publications revealing the 
transactivation or polycomb-independent role of EZH2 in breast cancer66,80, and 
prostate cancer56.  
 
The therapeutic potential of targeting pre-SET region of EZH2 in breast cancer 
The newly identified interaction of TRIM28 and EZH2 might contribute to the 
polycomb-independent role of EZH2 in breast cancer. The specific region of 
EZH2 interacting with TRIM28 is the pre-SET domain region (containing CXC 
domain); the pre-SET domain region of EZH2 was reported to direct SET domain 
activity in drosophila156.  And the name of “CXC domain” was originally coined to 
refer to the pre-SET motif of EZH2159 in drosophila. A previous structural study 
indicates that pre-SET region of EZH2 is critical to associate with SUZ12, and 
AEBP2 157. The TRIM28 interaction with pre-SET domain (CXC) region of EZH2 
in mammalian cells indicates that TRIM28 might also direct SET domain activity, 
global H3K27me3 binding profiling indicates that TRIM28 regulates H3K27me3 
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localization in breast cancer cells, might potentiate chromatin status to promote 
breast cancer progression.  
 
Further, TRIM28 might potentially switch EZH2’s affinity to histone substrate or 
non-histone substrates. Thus, targeting EZH2/TRIM28 interaction could be a 
better approach to dampen breast cancer progression than targeting SET 
domain along. This new knowledge collaborates with our study here may inspire 
a new strategy of EZH2 inhibitor design that should more efficiently target the 
activation function domain of EZH2. More precisely, there is potential 
involvement of sumoylation pathway in TRIM28/EZH2 interaction in breast 
cancer cells. Previously, sumoylation pathway was reported to be required in 
breast cancer 182,189.  
 
A very recent publication80 of investigating mechanism of EZH2 expanding breast 
cancer stem cell discovered NOTCH signaling as EZH2’s H3K27me3 
independent targets. Here we report to identify CXCR4/CXCL12 pathway as 
EZH2’s H3K27me3 independent targets. The possible reason of this discrepancy 
is probably due to the technical limitation of specific stem cell signaling focused 
PCR array they employed.  
 
The positive role of TRIM28 in breast cancer stem cell maintenance 
This dissertation reports the function of TRIM28 in breast cancer stem cell 
biology. On the other hand, there are at least two publications highlighted that 
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TRIM28 implicated in embryonic stem cell biology114,115. In general, cancer stem 
cell tends to phenocopy embryonic stem cell, if we link SOX2 from stem cell to 
cancer stem cell160. Additionally, our data indicate that mutant EZH2 of deleting 
the interaction domain with TRIM28 show very limited capacity to form 
mammosphere. This data show that EZH2/TRIM28 interaction might be critical 
for breast cancer stem cell maintenance. Thus, targeting EZH2/TRIM28 
interaction is a very useful approach to dampen breast cancer progression. 
Breast cancer stem cell represents the novel direction of drug resistant breast 
cancer therapy development. The newly identified breast cancer stem cell 
regulatory molecule could be a potential therapeutic target. Thus, this study 
brings unparalleled value to the community.  
 
On the other hand, TRIM28 was published to promote breast cancer proliferation 
and metastatic progression144, we reported here that TRIM28 regulated breast 
cancer proliferation is actually phosphorylation dependent. But whether the 
metastasis regulation of TRIM28 is also dependent on its phosphorylation status 
remains to be investigated.  
 
There is huge potential of TRIM28 in breast cancer research since TRIM28 
express in the epithelial cells, but not in the myoepithelial cells indicated by IHC 
staining of human normal breast. However TRIM28 express at both myoepithelial 
and epithelial cells in luminal A, luminal B, HER2, Basal type breast cancers. So, 
for myoepithelial cells, TRIM28 protein expression is gradually increased from 
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normal cells to malignant breast cancer cells, which is the classical characteristic 
of oncogenic protein. Most of malignant types of breast cancer, especially basal 
type breast cancer are mixed lineages with cells originated from both epithelial 
and myoepithelial cells14. So, it is reasonable to speculate that inhibition of 
TRIM28 in mixed lineage type of breast cancer might be able to reverse the 
myoepithelial origined cancer cells back to normal.  
 
From the perspective of development biology, myoepithelial cells are reported to 
originate from epithelial cells185,186, the unique expression pattern of TRIM28 
suggests that TRIM28 might play a critical role in epithelial cells’ differentiation 
into myoepithelial cells. In addition, basal lineage breast cancer is derived from 
myoepithelial cells 14,187; this raises a possibility that TRIM28 might involve in the 
programming of luminal type breast cancer into basal type breast cancer. 
 
The existence of non-histone substrates of EZH2 in breast cancer is high likely. 
There are potentially more unknown substrates in breast cancer to contribute to 
tumorigenesis; our proteomics study in breast cancer cells provided a few 
candidate substrates, the SWI/SNF complex members are high likely to be one 
or more of the non-histone substrates of EZH2.  
 
The potential application of TRIM28/EZH2 axis in X chromosome inactivation 
Since EZH2 is involved in X chromosome inactivation190, most of PRC2 
associated proteins and long noncoding RNAs play a critical role in XCI. So, it is 
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possible that TRIM28, as a specific associated protein of EZH2, might also 
contribute to X chromosome inactivation. EZH2 is known to directly regulate DNA 
methylation in whole genome wide191; there is a report that TRIM28 KO displayed 
reprogramming defect of embryo through single cell DNA methylation analysis192. 
It is possible that TRIM28/EZH2 coordinately involve in early epigenetic 
reprogramming during embryo development, but the details need to be further 
investigated. 
 
The investigation of overcoming resistance of breast cancer treatment is in 
extremely high demand. Previous publications showed that EZH2 is over-
expressed in various cancers such as melanoma, lymphoma, and prostate and 
breast cancer. EZH2 is a marker of aggressive breast cancer. Overexpression of 
EZH2 also promotes neoplastic transformation of normal prostatic cells and 
hyperplasia in breast epithelium. As an oncogene, EZH2 inhibitor as a promising 
anti-cancer drug is being extensively researched and developed in the 
pharmaceutical industry. However, this depth of knowledge is essential for 
rational development of EZH2-targeted therapeutics of various subtypes of 
breast cancers. The deeper understanding of EZH2 regulation by further study is 
of interest for cancer patients. This research will set a fundamental stage for 
instructing EZH2 inhibitor development against resistant breast cancer. 
 
It is extremely intriguing that TRIM28 express in the epithelial cells, but not in the 
myoepithelial cells indicated by IHC staining of human normal breast, but 
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express at both myoepithelial and epithelial cells in luminal A, luminal B, HER2, 
Basal type breast cancers; since myoepithelial cells is reported to originate from 
epithelial cells185,186, the unique expression pattern of TRIM28 suggests that 
TRIM28 might play an important role in epithelial cells’ differentiation into 
myoepithelial cells. In addition, basal lineage breast cancer is derived from 
myoepithelial cells 14,187; this raises a possibility that TRIM28 might involve in the 
programming of luminal type breast cancer into basal type breast cancer. 
 
This suggests that TRIM28 might only regulate myoepithelial lineage in normal 
mammary tissue, but promotes bi-lineage identify in breast cancer tissues. 
However, EZH2 was reported to promote a bi-lineage identity in basal-like breast 
cancer cells 193.  
 
The potential role of EZH2 as a lineage factor, not the real cancer stem cell self-
renewal maintenance factor?  
Unphosphorylated form of TRIM28 interact with EZH2 reveals the EZH2 
dependent TRIM28 regulatory role in cancer stem cell maintenance. However, 
the phosphorylated form of TRIM28 loses interaction with EZH2, and still 
promotes mammosphere formation, in comparison with the phosphorylation 
defected form of TRIM28. This leads us to hypothesize phosph-TRIM28 govern 
cancer stem cell maintenance through an EZH2 independent pathway.  If this is 
true, p-TRIM28 and EZH2 are regulating two parallel, two different pathways, 
these two different signals could not both involved in cancer stem cell 
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maintenance. If phosphorylation-TRIM28 is regulating cancer stem cell 
maintenance, EZH2 should be less pluripotent, and then might be a lineage 
factor. 
 
The potential link between H3K27me3 and H3K9me3 
We showed that TRIM28 interacts with EZH2 to regulate H3K27me3 distribution 
here, which may correlate with bivalent chromatin signature, a feature of 
embryonic stem cell 94. This leads us to examine the role of TRIM28 in cancer 
stem cell maintenance. The global histone modification profiling analysis 
indicates that TRIM28 global binding profile is highly correlated with H3K9me3 
binding profile. Thus, TRIM28 links H3K9me3 with H3K27me3 histone 
modifications in breast cancer cells. To my knowledge, this is the first direct 
experimental evidence to show the crosstalk between H3K27me3 and H3K9me3. 
It was reported that there are a couple of indirect observations that link H3K9me3 
with H3K27me3 before in drosophila 194. SUZ112 links HP1α with EZH2 in fly 195, 
which imply the crosstalk between H3K9me3 and H3K27me3. More recently, 
EZH2 and SUZ12 were showed to be required for HP1α stability in mouse tissue 
196. In vitro peptides binding assay demonstrates that HP1α/β/γ binding affinity 
with H3K9me3 was greatly increased with the presence of H3K27me3 peptide. 
So, it is likely that a cooperative mechanism of H3K9 and H3K27 residues may 
exist, connected by HP1α anchorage at chromatin 196. 
 
Future Directions: 
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The following questions might be able to guild us to think deeper. 
1. Does EZH2/TRIM28 mediated transcriptional activation involves p300 
recruitment? Because p300 appear in the dataset of the latest EZH2 purification. 
2. Which Zinc Finger protein recruited EZH2/TRIM28? 
Would it be RBP-J, Notch pathway, or TCF4, Wnt pathway? Since Motif analysis 
of TRIM28 ChIP-seq identified these two binding motifs.   
3. Are cluster 1 genes (including some of the lincRNAs) functionally similar to 
ESR1, PgR? Mediating luminal epithelial differentiation?  
4. Does H3K9me3 connect with H3K27me3 in breast cancer? And how? 
5. EZH2 interacts with SWI/SNF, NURD complex directly or indirectly? 
6. If the interaction is indirect, does TRIM28 act as a scaffold protein linking 
EZH2 and SWI/SNF complex? 
7. Does EZH2 methylate itself? Does EZH2 methylate PBRM1? BRG1? Dicer1? 
8. How TRIM28 destabilize the interaction of EZH2 and BRG1?  
9. Does TRIM28 sumoylate EZH2? 
10. Whether EZH2 only interact with sumoylated TRIM28? Or both unsumoylated 
and sumoylated form of TRIM28?  
11. RBCC motif binds KRAB Zinc Finger proteins, and EZH2, does ZFP compete 
with EZH2 to bind with TRIM28?  
12. Is there more Cancer Stem Cell marker genes in the gene list jointly down-
regulated by EZH2/TRIM28? Does EZH2/TRIM28 co-mark a gene set which is 
very critical for cancer stem cell? 
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Chapter Six: Conclusion 
Targeting the highly expressed EZH2 in breast cancer might provide a useful 
strategy to overcome resistance of breast cancer. However, this depth of 
knowledge is essential for rational development of EZH2-targeted therapeutics of 
various subtypes of breast cancers. The deeper understanding of EZH2 
regulation by further study is of interest for cancer patients. EZH2 was believed 
to contribute to tumor progression via its H3K27me3 dependent transcriptional 
repressive program for a long time. But there are argument claiming that the 
oncogenic function of EZH2 is independent of H3K27me3. We observed the 
similar results of inconsistent correlation of EZH2 and H3K27me3 levels in breast 
cancer in both cell lines and human breast cancer tissue array. This indicates the 
possible existence of non-histone substrates of EZH2 as a methyltransferase in 
breast cancer. This is the further validation of some of the previous publications 
revealing the transactivation or polycomb-independent role of EZH2 in breast 
cancer, and prostate cancer.  
 
In the first part of my dissertation, I demonstrated that the newly identified 
interaction of TRIM28 and EZH2 might contribute to the polycomb-independent 
role of EZH2 in breast cancer, and this interaction was also reported in prostate 
cancer. The specific region of EZH2 interacting with TRIM28 is the pre-SET 
domain region (containing CXC domain). The H3K27me3 redistribution was 
observed in TRIM28 depleted MCF7 cells. Three clusters of genes with 
H3K27me3 gains, loss, and flat upon TRIM28 depletion was described. 
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Functionally, through transcriptome study, TRIM28 mediated EZH2 function was 
pinpointed to maintenance of the breast cancer stem cells via transcriptionally 
activation of CXCR4. We identify CXCR4/CXCL12 pathway as EZH2’s 
H3K27me3 independent targets in cancer cells. The pre-SET domain region of 
EZH2 was reported to direct SET domain activity in drosophila. The TRIM28 
regulation pre-SET domain (CXC) region of EZH2 in mammalian system 
indicates that targeting EZH2/TRIM28 interaction could be a better approach to 
dampen breast cancer progression than targeting SET domain. This new 
knowledge collaborates with our study here may inspire a new strategy of EZH2 
inhibitor design that should target the activation function domain of EZH2. 
 
In the second part of my dissertation, I demonstrated that unphosphorylated form 
of TRIM28 interact with EZH2 which reveals the EZH2 dependent TRIM28 
regulatory role in cancer stem cell maintenance. However, the phosphorylated 
form of TRIM28 loses interaction with EZH2, and still promotes mammosphere 
formation, in comparison with the phosphorylation defected form of TRIM28.  
Phosph-TRIM28 might govern breast cancer stem cell maintenance through an 
EZH2 independent pathway.  Previously, TRIM28 was published to promote 
breast cancer proliferation and metastatic progression, we did invasion and 
metastasis assays in our lab, the TRIM28 mediated effect of metastatic 
progression is relatively marginal in MCF7 cells, compared with the regulation of 
CSC feature with TRIM28. And the proliferation regulation function part of it is still 
controversial, as Douglas Cress published that TRIM28 actually suppress MDA-
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MB-231 cells proliferation. So the proliferation regulation of TRIM28 could be cell 
line dependent effect, or post-translational modification dependent effect of 
TRIM28. The post-translational modification of TRIM28 effect on breast cancer 
progression needs to be further characterized. And another question still remains 
whether TRIM28 mediated breast cancer promotion is dependent on the 
expansion of breast cancer stem cell or some other mechanisms?  
 
TRIM28 gnomically binds on the same motif of RBPJ, this might directly repress 
Wnt/AXIN2 pathway. It is extremely intriguing that TRIM28 express in the 
epithelial cells, but not in the myoepithelial cells indicated by IHC staining of 
human normal breast, but express at both myoepithelial and epithelial cells in 
luminal A, luminal B, HER2, Basal type breast cancers; since myoepithelial cells 
is reported to originate from epithelial cells, the unique expression pattern of 
TRIM28 suggests that TRIM28 might play an important role in epithelial cells’ 
differentiation into myoepithelial cells. In addition, basal lineage breast cancer is 
derived from myoepithelial cells. This suggests that TRIM28 might only regulate 
myoepithelial lineage in normal mammary tissue, but promotes bi-lineage identify 
in breast cancer tissues. In contrast, EZH2 was reported to promote a bi-lineage 
identity in basal-like breast cancer cells.  
 
Additionally, the marginal effect of GSK126 inhibition of mammosphere formation 
in MCF7 suggests the existence of non-histone substrates of EZH2 in luminal 
type breast cancer. Whereas Stuart Orkin‘s antiproliferative experiments of GSK-
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126 on MDA-MB-231 cells appear no effect at all. The discrepancy here indicates 
the anti-breast cancer effect of GSK-126 is cell line dependent, as two very 
recent publications demonstrated. Another possibility is that there are potentially 
more unknown substrates in breast cancer to contribute to tumorigenesis; the 
SWI/SNF complex members are high likely to be one of the non-histone 
substrates.  
 
Collectively, in my dissertation, I reported that EZH2 interacts with TRIM28 in a 
catalytic domain dependent manner in breast cancer cells. Further study 
indicates that TRIM28 reprogram H3K27me3 distribution in breast cancer cells. 
TRIM28 interacts with EZH2 to maintain breast cancer stem cell phenotype 
through collaboratively transcriptional activation of CXCR4 cancer stem cell 
signaling pathway. This is the very first data to report the function of TRIM28 in 
breast cancer stem cell biology. In the other hand, there are at least two 
publications highlighted that TRIM28 implicated in embryonic stem cell biology. In 
general, cancer stem cell tends to phenocopy embryonic stem cell, if we link 
SOX2 from stem cell to cancer stem cell. Additionally, our data indicate that 
mutant EZH2 of deleting the interaction domain with TRIM28 show very limited 
capacity to form mammosphere.  The deeper understanding of EZH2 regulation 
by further study is of interest for cancer patients. This data show that 
EZH2/TRIM28 interaction is critical for breast cancer stem cell maintenance. 
Thus, targeting EZH2/TRIM28 interaction is a very useful approach to dampen 
breast cancer progression. Breast cancer stem cell represents the novel direction 
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of drug resistant breast cancer therapy development. The newly identified breast 
cancer stem cell regulatory axis could be a potential therapeutic target. Thus, this 
study brings unparalleled value to the community. This research will set a 
fundamental stage for instructing EZH2 inhibitor development against resistant 
breast cancer. 
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